JP2012197231A - Pyridine and pyrimidine derivative having ttk-inhibiting action - Google Patents

Pyridine and pyrimidine derivative having ttk-inhibiting action Download PDF

Info

Publication number
JP2012197231A
JP2012197231A JP2010121046A JP2010121046A JP2012197231A JP 2012197231 A JP2012197231 A JP 2012197231A JP 2010121046 A JP2010121046 A JP 2010121046A JP 2010121046 A JP2010121046 A JP 2010121046A JP 2012197231 A JP2012197231 A JP 2012197231A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
formula
1a
1h
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010121046A
Other languages
Japanese (ja)
Inventor
Kenichi Kusakabe
Naoko Yamaguchi
Yasunori Mitsuoka
恭典 三岡
奈緒子 山口
兼一 日下部
Original Assignee
Oncotherapy Science Ltd
オンコセラピー・サイエンス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009183833 priority Critical
Priority to JP2009183833 priority
Application filed by Oncotherapy Science Ltd, オンコセラピー・サイエンス株式会社 filed Critical Oncotherapy Science Ltd
Priority to JP2010121046A priority patent/JP2012197231A/en
Publication of JP2012197231A publication Critical patent/JP2012197231A/en
Application status is Pending legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • C07D213/85Nitriles in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Abstract

PROBLEM TO BE SOLVED: To provide an effective inhibitor of TTK protein kinase, and to provide an effective medicine.SOLUTION: There is provided a pyridine derivative or pyrimidine derivative represented by formula (I). (Wherein, X is =C(R4)- or =N-; A is a substituted or non-substituted aromatic hydrocarbon ring, substituted or non-substituted aromatic heterocycle (wherein, excluding substituted or non-substituted pyrazole or condensed pyrazole), substituted or non-substituted non-aromatic hydrocarbon ring or substituted or non-substituted non-aromatic heterocycle). The compound inhibits the action of TTK protein kinase, and is especially useful for preparing medicines for treating related diseases.

Description

  The present invention relates to pyridine and pyrimidine derivatives having an inhibitory / suppressing action on TTK (TTK protein kinase) activity. In another aspect, the present invention relates to a medicament comprising this pyridine and pyrimidine derivative.

  Protein kinases are enzymes that add (phosphorylate) phosphate groups to other protein molecules. Protein kinases have an activity of transferring a phosphate group from ATP to a hydroxyl group at an amino acid residue in a protein molecule to covalently bond it. Many protein kinases react with hydroxyl groups of serine and threonine in protein molecules (serine / threonine kinase), react with hydroxyl groups of tyrosine (tyrosine kinase), react with all three types (dual specificity) Kinase). The activity of protein kinases is precisely regulated, and protein kinases themselves may be regulated by phosphorylation. These modulations are caused by binding of other activating (or suppressing) proteins and low molecular weight compounds, localization changes in cells, and the like. Kinase dysfunction often causes illness.

  TTK protein kinase is a bispecific kinase that phosphorylates serine, threonine and tyrosine residues in a protein serving as a substrate (see, for example, Non-Patent Document 1). Kinase domains required for expressing kinase activity are known (see, for example, Non-Patent Documents 1 and 2). As endogenous substrates, Mad1 (for example, see Non-Patent Document 3), Spcl10p (Nuflp) (for example, Non-Patent Document 4), CHK2 (for example, Non-Patent Document 5), Borealin (for example, Non-Patent Document 6) For example). TTK expression correlates with cell proliferation and plays a role in cell cycle control. Patent Document 1 describes that TTK is expressed in malignant ovarian cancer and a screening method including a step of measuring the expression level of TTK. Patent Document 2 discloses an application relating to a method for identifying cancer cells by detecting TTK activity and a method for identifying a drug that suppresses tumor growth, and TTK using tau, cdc25, and their partial peptides as a substrate as a screening method. An activity measurement method is described. Patent Document 3 describes a method for measuring TTK activity using a partial peptide of p38MAPK as a substrate as a method for cleaning TTK activity. Examples of the TTK inhibitor include those described in Patent Documents 4 and 5.

  Examples of pyridine and pyrimidine derivatives include those described in Patent Documents 6 to 59 and Non-Patent Documents 7 to 20, but none are known as TTK inhibitors, and Patent Document 60 discloses TTK inhibitory activity. Is not described.

International Publication No. 01/94629 Pamphlet International Publication No. 02/068444 Pamphlet JP 2007-104911 A International Publication No. 2009/024824 Pamphlet International Publication No. 2009/032694 Pamphlet International Publication No. 2009/073575 Pamphlet International Publication No. 2008/129255 Pamphlet International Publication No. 2008/054292 Pamphlet International Publication No. 2008/053812 Pamphlet International Publication No. 2006/118231 Pamphlet International Publication No. 2006/087538 Pamphlet International Publication No. 2006/083392 Pamphlet International Publication No. 2006/117560 Pamphlet International Publication No. 2009/007029 Pamphlet International Publication No. 2008/156726 Pamphlet International Publication No. 2007/109355 Pamphlet International Publication No. 2006/081388 Pamphlet International Publication No. 2006/0776646 Pamphlet International Publication No. 2006/042289 Pamphlet International Publication No. 2007/077005 Pamphlet International Publication No. 2003/080564 Pamphlet German Patent Invention Application No. 3111937 British Patent No. 1405308 International Publication No. 98/28257 Pamphlet International Publication No. 94/15936 Pamphlet International Publication No. 98/37150 Pamphlet International Publication No. 95/07318 Pamphlet International Publication No. 94/20469 Pamphlet German Patent Invention Publication No. 3528759 German Patent Invention Application No. 3201268 European Patent No. 43575 European Patent Application No. 35172 German Patent Application Publication No. 2454492 German Patent Invention Application No. 2438130 Polish Provisional Patent No. 133955 Specification Japanese Patent Publication No.49-094677 German patent invention No. 22602727 US Pat. No. 3,853,895 German Patent Invention Application No. 2230392 International Publication No. 2003/002544 Pamphlet International Publication No. 2004/014382 Pamphlet French Patent Invention Application No. 2042360 Specification DE Patent Application Publication No. 2015955 Specification International Publication No. 2009/012421 Pamphlet International Publication No. 2008/107096 Pamphlet International Publication No. 2004/056786 Pamphlet International Publication No. 2004/048343 Pamphlet International Publication No. 2003/063794 Pamphlet International Publication No. 2003/037877 Pamphlet International Publication No. 2003/032997 Pamphlet International Publication No. 2003/002544 Pamphlet European Patent No. 135472 International Publication No. 2007/071455 Pamphlet International Publication No. 2007/003596 Pamphlet JP 2006-241089 A International Publication No. 2006/034872 Pamphlet International Publication No. 2002/096887 Pamphlet International Publication No. 2002/004429 Pamphlet International Publication No. 2004/065378 Pamphlet International Publication No. 2009/0675547 Pamphlet

Mills et al., J. Biol. Chem. (1992) 267,16000-16006 Lindberg et al., Oncogene (1993) 8,351-359 Liu et al., Mol. Biol. Cell. (2003) 14,1638-51 Friedman et al., J. Biol. Chem. (2001) 276, 17958-17967 Wei et al., J. Biol. Chem. (2005) 280,7748-7757 Jelluma et al., Cell (2008) 25,233-246 Gozgit et al., Journal of Biological Chemistry (2008), 283 (47), 32334-32343 Rickborn et al., Organic Reactions (1998), 53 Garcia et al., Synlett (2001), (1), 57-60 Cobo et al., Tetrahedron (1997), 53 (24), 8225-8236 Cobo et al., Tetrahedron (1996), 52 (16), 5845-5856 Low et al., Acta Crystallographica (1996), C52 (1), 145-148 Cobo et al., Synlett (1993), (4), 297-299 Kim et al., Journal of the Korean Fiber Society (2000), 37 (5), 293-300 Akagi et al., Nippon Noyaku Gakkaishi (1995), 20 (3), 279-290 Nagajima et al., ACS Symposium Series (1995), 584, 443-448 Guo et al., Journal of Organic Chemistry (1991), 56 (11), 3692-3700 Walker et al., Bioorganic & Medicinal Chemistry Letters (2008) 18 (23), 6071-6077 Arvanitis et al., Journal of Combinatorial Chemistry (2004), 6 (3), 414-419 Boschelli et al., Journal of Medicinal Chemistry (1998), 41 (22), 4365-4377

  An object of the present invention is to provide an effective inhibitor of TTK protein kinase, and thus to provide an effective medicament.

  The above problems have been solved by the compounds provided in the present invention and related inventions (eg, pharmaceutical compositions, TTK inhibitors, etc.).

  The Applicant has discovered a new series of compounds with specific properties that inhibit the action of TTK kinases and make them particularly useful for formulating pharmaceuticals for treating the above diseases. Therefore, the present compounds are useful in diseases that are considered effective by inhibiting the action of TTK kinase.

  Therefore, for example, the present invention provides the following items.

  (1A) Formula (I):

(In the formula, X is = C (R 4 )-or = N-, A is a substituted or unsubstituted aromatic hydrocarbon ring, a substituted or unsubstituted aromatic heterocyclic ring (however, a substituted or unsubstituted aromatic ring) Except for pyrazole or fused pyrazole.), A substituted or unsubstituted non-aromatic hydrocarbon ring or a substituted or unsubstituted non-aromatic heterocyclic ring,
R 1 is hydrogen, substituted or unsubstituted alkyl, a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B ;
R 1A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl or substituted or Unsubstituted saturated heterocyclyl,
R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted A substituted saturated heterocyclyl;
R 1B is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted Of saturated heterocyclyl
R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted Carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino, halogen, carboxy or hydrogen, or
R 1 and R 2 together with the adjacent carbon atom
Formula (II):

Wherein R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted Acyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl, R a and R b are each independently hydrogen or substituted or unsubstituted alkyl, and n is 0-3. Which may be an integer).
R 3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or halogen;
R 4 is hydrogen or halogen;
R 5A and R 5B are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl Substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, substituted or unsubstituted acyl, substituted or unsubstituted alkoxy, substituted or unsubstituted Carbamoyl, a group represented by the formula: —SO 2 —R ′, a group represented by the formula: —SO—R ′, or a group represented by the formula: —SR ′;
R ′ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl It is.
However,
(I) X is ═C (R 4 ) —, and A is substituted or unsubstituted piperidine, substituted or unsubstituted thiophene, substituted or unsubstituted tetrahydropyran, substituted or unsubstituted fused pyrimidine, substituted or non-substituted When substituted condensed pyridine or substituted or unsubstituted tetrahydrofuran, R 2 is cyano;
(Ii) when X is ═C (R 4 ) —, A is a substituted or unsubstituted aromatic hydrocarbon ring, and R 2 is nitro, R 1 is of the formula: —NR 1A R 1A ′ In which R 1A ′ is phenylethyl and the group represented by the formula: —OR 1B (where R 1B is methyl)
(Iii) When X is ═C (R 4 ) — and A is a substituted or unsubstituted non-aromatic hydrocarbon ring, R 1 is a group represented by the formula: —NR 1A R 1A ′ (here R 1A ′ is substituted or unsubstituted alkyl) and a group represented by the formula: —OR 1B (where R 1B is substituted or unsubstituted alkyl),
(Iv) X is ═C (R 4 ) —, A is a substituted or unsubstituted aromatic hydrocarbon ring, R 2 is cyano, and R 1 is represented by the formula: —NR 1A R 1A ′ Wherein R 1A ′ is a substituted or unsubstituted alkyl or a group of the formula: —OR 1B (where R 1B is methyl or ethyl), R 3 is hydrogen,
(V) When X is ═C (R 4 ) — and A is a non-aromatic heterocyclic ring, R 1 is a group represented by the formula: —NR 1A R 1A ′ (where R 1A ′ is Instead of substituted or unsubstituted alkyl)
(Vi) when X is ═C (R 4 ) —, the number of hydrogens in R 1 , R 3 and R 4 is 2 or less;
(Vii) When X is = N-, A is a substituted or unsubstituted aromatic hydrocarbon ring or a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyridine). , R 2 is cyano, R 3 is hydrogen, R 1 is a group represented by the formula: —NR 1A R 1A ′ (where R 1A ′ is a substituted or unsubstituted alkyl, substituted or unsubstituted Piperidinyl and substituted or unsubstituted cyclopropyl) and a group represented by the formula: —OR 1B (where R 1B is substituted or unsubstituted alkyl),
(Viii) When X is = N-, A is a substituted or unsubstituted aromatic hydrocarbon ring or a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyridine). , R 2 is cyano, R 3 is hydrogen and R 5A is not substituted sulfinyl, substituted or unsubstituted carbamoyl, carboxy, substituted or unsubstituted morpholinyl and substituted sulfonyl.
) A compound represented by the following formula (however, the compound shown below:

except for. ), A pharmaceutically acceptable salt thereof, or a solvate thereof.

(2A) R 1 is a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B (wherein R 1A , R 1A ′ and R 1B are as defined in item (1A)) Yes,
R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted The compound according to item (1A), its pharmaceutically acceptable salt, or a solvate thereof, which is carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino or carboxy.

  (3A) The compound according to item (1A) or (2A), pharmaceutically acceptable salt or solvate thereof, wherein A is a substituted or unsubstituted aromatic hydrocarbon ring.

(4A) The compound according to any one of items (1A) to (3A), wherein X is ═C (R 4 ) — (where R 4 has the same meaning as item (1A)), and a pharmaceutically acceptable product thereof Salts or solvates thereof.

  (5A) The compound according to any one of items (1A) to (4A), pharmaceutically acceptable salt or solvate thereof, wherein X is = CH-.

(6A) R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted The compound according to any one of items (1A) to (5A), a pharmaceutically acceptable salt thereof, or a solvate thereof, which is alkoxycarbonyl, substituted amino or carboxy.

(7A) The compound according to any one of items (1A) to (6A), pharmaceutically acceptable salt or solvate thereof, wherein R 2 is cyano.

(8A) The compound according to any one of items (1A) to (7A), a pharmaceutically acceptable salt or a solvate thereof, wherein R 3 is hydrogen.

(8′A) The compound according to any one of items (1A) to (7A), a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R 3 is substituted or unsubstituted alkyl.

(9A) R 1 has the formula: -NHR 1A 'in a group represented by or formula group (wherein, R 1A represented by -OR 1B' and R 1B item (1A) and synonymous) is, items (1A ) To (8A) and (8′A), a pharmaceutically acceptable salt thereof, or a solvate thereof.

(10A) R 1 is a group represented by the formula: —NHR 1A ′ , and R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted saturated heterocyclyl. The compound according to any one of items (1A) to (8A), (8′A) and (9A), a pharmaceutically acceptable salt thereof, or a solvate thereof.

(11A) R 1 has the formula: a group represented by -OR 1B, R 1B is a substituted or unsubstituted cycloalkyl, item (1A) ~ (8A), (8'A), and (9A) Or a pharmaceutically acceptable salt or solvate thereof.

  (12A) Formula (III):

A group represented by
Formula (IV):

Any one of items (1A) to (8A), (8′A), and (9A) to (11A), wherein R 5A and R 5B have the same meanings as item (1A) Or a pharmaceutically acceptable salt or solvate thereof.

(13A) In any of items (1A) to (8A), (8′A), and (9A) to (12A), wherein R 5A is substituted or unsubstituted heteroaryl or substituted or unsubstituted alkenyl The described compounds, pharmaceutically acceptable salts or solvates thereof.

(14A) Items (1A) to (8A), wherein R 5A is substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted alkenyl ), (8′A), and (9A) to (13A), a pharmaceutically acceptable salt thereof, or a solvate thereof.

(15A) The compound according to any one of items (1A) to (8A), (8′A), and (9A) to (14A), wherein R 5B is hydrogen or substituted or unsubstituted alkoxy, its pharmaceutical Top acceptable salts or solvates thereof.

(16A) X is = C (R 4 )-(where R 4 is synonymous with item (1A))
R 1 and R 2 together with adjacent carbon atoms
Formula (II):

Wherein R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl or substituted or unsubstituted cycloalkyl,
n is an integer of 0 to 2, R a and R b are the same as defined in item (1A)), A is a substituted or unsubstituted aromatic hydrocarbon ring;
R 3 is hydrogen, the compound according to any of items (1A) to (5A), (8A), (8′A), and (12A) to (15A), a pharmaceutically acceptable salt thereof, or Their solvates.

  (17A) A pharmaceutical comprising the compound according to any one of items (1A) to (8A), (8'A), (9A) to (16A), a pharmaceutically acceptable salt thereof or a solvate thereof Composition.

  (18A) The pharmaceutical composition according to item (17A), which is a TTK inhibitor.

  (19A) Formula (I):

Wherein X is = C (R 4 )-, A is a substituted or unsubstituted aromatic hydrocarbon ring, a substituted or unsubstituted aromatic heterocycle (provided that a substituted or unsubstituted pyrazole or fused pyrazole And substituted or unsubstituted thiophene), a substituted or unsubstituted non-aromatic hydrocarbon ring or a substituted or unsubstituted non-aromatic heterocyclic ring,
R 1 is hydrogen, substituted or unsubstituted alkyl, a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B ;
R 1A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl or substituted or Unsubstituted saturated heterocyclyl,
R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted A substituted saturated heterocyclyl;
R 1B is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted Of saturated heterocyclyl
R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted Carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino, halogen, carboxy or hydrogen, or
R 1 and R 2 together with the adjacent carbon atom
Formula (II):

(Where
R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted Or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl,
R a and R b are each independently hydrogen or substituted or unsubstituted alkyl;
n is an integer of 0-3. )
R 3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or halogen;
R 4 is hydrogen or halogen;
R 5A and R 5B are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl Substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, substituted or unsubstituted acyl, substituted or unsubstituted alkoxy, substituted or unsubstituted Carbamoyl, a group represented by the formula: —SO 2 —R ′, a group represented by the formula: —SO—R ′, or a group represented by the formula: —SR ′;
R ′ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl The pharmaceutical composition which has TTK inhibitory activity containing the compound which is these, its pharmaceutically acceptable salt, or those solvates.

  (20A) The pharmaceutical composition according to any of items (17A) to (19A), which is a medicament for the treatment or prevention of a disease, disorder or condition associated with TTK.

  (21A) The pharmaceutical composition according to any of items (17A) to (20A) for cancer treatment and / or prevention.

  (22A) administering the compound according to any one of items (1A) to (8A), (8′A), (9A) to (16A), a pharmaceutically acceptable salt thereof, or a solvate thereof. A method for preventing or treating cancer, characterized by:

  (23A) The compound according to any one of items (1A) to (8A), (8′A), (9A) to (16A) for the manufacture of a therapeutic and / or prophylactic agent for cancer, Use of a pharmaceutically acceptable salt or a solvate thereof.

  (24A) The compound according to any one of items (1A) to (8A), (8′A), (9A) to (16A) for treating and / or preventing cancer, its pharmaceutically acceptable Salts or solvates thereof.

  (25A) The compound according to any one of items (1A) to (8A), (8′A), (9A) to (16A), a pharmaceutically acceptable salt thereof, or a solvate thereof. TTK inhibitor.

  (26A) The compound according to any one of items (1A) to (8A), (8′A), (9A) to (16A), a pharmaceutically acceptable salt thereof, or a solvate thereof. Anti-cancer agent.

  (27A) The compound according to any one of items (1A) to (8A), (8′A), (9A) to (16A), a pharmaceutically acceptable salt thereof, or a solvate thereof. A therapeutic agent for immune system diseases.

  (28A) The compound according to any one of items (1A) to (8A), (8′A), (9A) to (16A), a pharmaceutically acceptable salt thereof, or a solvate thereof. Immunosuppressant.

  (29A) The compound according to any one of items (1A) to (8A), (8′A), (9A) to (16A), a pharmaceutically acceptable salt thereof, or a solvate thereof. A therapeutic agent for autoimmune diseases.

  (30A) A compound according to any one of items (1A) to (8A), (8'A), (9A) to (16A), a pharmaceutically acceptable salt thereof, or a solvate thereof is produced. Methods, systems, devices, kits etc.

  (31A) The compound according to any one of items (1A) to (8A), (8′A), (9A) to (16A), a pharmaceutically acceptable salt thereof, or a solvate thereof. Methods, systems, devices, kits, etc. for preparing pharmaceutical compositions.

  (32A) The compound according to any one of items (1A) to (8A), (8'A), (9A) to (16A), a pharmaceutically acceptable salt thereof, or a solvate thereof is used. Methods, systems, devices, kits etc.

  (33A) A method for preventing or treating cancer, comprising administering the pharmaceutical composition having TTK inhibitory activity according to item (19A).

  (1B) Formula (I):

(Where
X is = C (R 4 )-or = N-
A represents a substituted or unsubstituted aromatic hydrocarbon ring, a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyrazole or fused pyrazole), a substituted or unsubstituted non-aromatic hydrocarbon ring. Or a substituted or unsubstituted non-aromatic heterocycle,
R 1 is hydrogen, substituted or unsubstituted alkyl, a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B ;
R 1A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl or substituted or Unsubstituted saturated heterocyclyl,
R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Substituted saturated heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl,
R 1B is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Saturated heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl,
R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl , Substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino, halogen, carboxy or hydrogen, or
R 1 and R 2 together with the adjacent carbon atom
Formula (II):

(Where
R 1A ″ and R 2A ″ each independently represent hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl Substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl,
R a and R b are each independently hydrogen or substituted or unsubstituted alkyl;
n is an integer of 0-3. ) May be formed,
R 3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or halogen;
R 4 is hydrogen or halogen;
R 5A and R 5B are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, substituted or unsubstituted acyl, substituted or unsubstituted alkoxy, substituted or An unsubstituted carbamoyl, a group represented by the formula: —SO 2 —R ′, a group represented by the formula: —SO—R ′, or a group represented by the formula: —SR ′;
R ′ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl It is.
However,
(I) X is ═C (R 4 ) —, and A is substituted or unsubstituted piperidine, substituted or unsubstituted thiophene, substituted or unsubstituted tetrahydropyran, substituted or unsubstituted fused pyrimidine, substituted or non-substituted When substituted condensed pyridine or substituted or unsubstituted tetrahydrofuran, R 2 is cyano;
(Ii) when X is ═C (R 4 ) —, A is a substituted or unsubstituted aromatic hydrocarbon ring, and R 2 is nitro, R 1 is of the formula: —NR 1A R 1A ′ In which R 1A ′ is phenylethyl and the group represented by the formula: —OR 1B (where R 1B is methyl)
(Iii) When X is ═C (R 4 ) — and A is a substituted or unsubstituted non-aromatic hydrocarbon ring, R 1 is a group represented by the formula: —NR 1A R 1A ′ (here R 1A ′ is substituted or unsubstituted alkyl) and a group represented by the formula: —OR 1B (where R 1B is substituted or unsubstituted alkyl),
(Iv) X is ═C (R 4 ) —, A is a substituted or unsubstituted aromatic hydrocarbon ring, R 2 is cyano, and R 1 is represented by the formula: —NR 1A R 1A ′ Wherein R 1A ′ is a substituted or unsubstituted alkyl or a group of the formula: —OR 1B (where R 1B is methyl or ethyl), R 3 is hydrogen,
(V) When X is ═C (R 4 ) — and A is a non-aromatic heterocyclic ring, R 1 is a group represented by the formula: —NR 1A R 1A ′ (where R 1A ′ is Instead of substituted or unsubstituted alkyl)
(Vi) when X is ═C (R 4 ) —, the number of hydrogens in R 1 , R 3 and R 4 is 2 or less;
(Vii) When X is = N-, A is a substituted or unsubstituted aromatic hydrocarbon ring or a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyridine). , R 2 is cyano, R 3 is hydrogen, R 1 is a group represented by the formula: —NR 1A R 1A ′ (where R 1A ′ is a substituted or unsubstituted alkyl, substituted or unsubstituted Piperidinyl and substituted or unsubstituted cyclopropyl) and a group represented by the formula: —OR 1B (where R 1B is substituted or unsubstituted alkyl),
(Viii) When X is = N-, A is a substituted or unsubstituted aromatic hydrocarbon ring or a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyridine). , R 2 is cyano, R 3 is hydrogen and R 5A is not substituted sulfinyl, substituted or unsubstituted carbamoyl, carboxy, substituted or unsubstituted morpholinyl and substituted sulfonyl.
) A compound represented by the following formula (however, the compound shown below:

except for. ), A pharmaceutically acceptable salt thereof, or a solvate thereof.

(2B) R 1 is a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B (wherein R 1A , R 1A ′ and R 1B are as defined in item (1B)). Yes,
R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl , A substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino or carboxy, a pharmaceutically acceptable salt thereof or a solvent thereof Japanese products.

  (3B) The compound according to item (1B) or (2B), pharmaceutically acceptable salt or solvate thereof, wherein A is a substituted or unsubstituted aromatic hydrocarbon ring.

(4B) The compound according to any one of items (1B) to (3B), wherein X is ═C (R 4 ) — (where R 4 has the same meaning as item (1B)), and a pharmaceutically acceptable salt thereof. Salts or solvates thereof.

  (5B) The compound according to any one of items (1B) to (4B), a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein X is = CH-.

(6B) R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbamoyl, substituted or unsubstituted The compound according to any one of items (1B) to (5B), a pharmaceutically acceptable salt thereof, or a solvate thereof, which is acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino or carboxy.

(7B) The compound according to any one of items (1B) to (6B), a pharmaceutically acceptable salt or a solvate thereof, wherein R 2 is cyano.

(8B) The compound according to any one of items (1B) to (7B), a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R 3 is hydrogen.

(9B) R 1 has the formula: -NHR 1A 'in a group represented by or formula group (wherein, R 1A represented by -OR 1B' and R 1B item (1B) and synonymous) is, item (1B ) To (8B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

(10B) R 1 is a group represented by the formula: —NHR 1A ′ , and R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted saturated heterocyclyl. The compound according to any one of items (1B) to (9B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

(11B) R 1 has the formula: a group represented by -OR 1B, R 1B is a substituted or unsubstituted cycloalkyl A compound according to any of items (1B) ~ (10B), a pharmaceutically Acceptable salts or solvates thereof.

  (12B) Formula (III):

A group represented by
Formula (IV):

Or a pharmaceutically acceptable salt thereof, or a compound thereof according to any one of items (1B) to (11B), wherein R 5A and R 5B are as defined in item (1B) Solvate.

(13B) The compound according to any one of items (1B) to (12B), a pharmaceutically acceptable salt thereof, or a solvent thereof, wherein R 5A is substituted or unsubstituted heteroaryl or substituted or unsubstituted alkenyl. Japanese products.

(14B) Items (1B) to (13B), wherein R 5A is substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted alkenyl. ), A pharmaceutically acceptable salt thereof, or a solvate thereof.

(15B) The compound according to any one of items (1B) to (14B), wherein R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl, or a pharmaceutically acceptable salt thereof Acceptable salts or solvates thereof.

(16B) X is = C (R 4 )-(where R 4 is synonymous with item (1B)),
R 1 and R 2 together with adjacent carbon atoms
Formula (II):

Wherein R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl or substituted or unsubstituted cycloalkyl,
n is an integer of 0 to 2, and R a and R b form a group represented by the item (1B)),
A is a substituted or unsubstituted aromatic hydrocarbon ring,
The compound according to any one of items (1B) to (15B), a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R 3 is hydrogen.

  (17B) A pharmaceutical composition comprising the compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

  (18B) The pharmaceutical composition according to item (17B), which is a TTK inhibitor.

  (19B) Formula (I):

(Where
X is = C (R 4 )-
A represents a substituted or unsubstituted aromatic hydrocarbon ring, a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyrazole or fused pyrazole and substituted or unsubstituted thiophene), substituted or unsubstituted A non-aromatic hydrocarbon ring or a substituted or unsubstituted non-aromatic heterocyclic ring,
R 1 is hydrogen, substituted or unsubstituted alkyl, a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B ;
R 1A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl or substituted or Unsubstituted saturated heterocyclyl,
R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted A substituted saturated heterocyclyl;
R 1B is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted Of saturated heterocyclyl
R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl , Substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino, halogen, carboxy or hydrogen, or
R 1 and R 2 together with the adjacent carbon atom
Formula (II):

(Where
R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted Or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl,
R a and R b are each independently hydrogen or substituted or unsubstituted alkyl;
n is an integer of 0-3. )
R 3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or halogen;
R 4 is hydrogen or halogen;
R 5A and R 5B are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl Substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, substituted or unsubstituted acyl, substituted or unsubstituted alkoxy, substituted or unsubstituted Carbamoyl, a group represented by the formula: —SO 2 —R ′, a group represented by the formula: —SO—R ′, or a group represented by the formula: —SR ′;
R ′ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl The pharmaceutical composition which has TTK inhibitory activity containing the compound which is these, its pharmaceutically acceptable salt, or those solvates.

  (20B) The pharmaceutical composition according to any one of items (17B) to (19B), which is a medicament for treating or preventing a disease, disorder or condition associated with TTK.

  (21B) The pharmaceutical composition according to any of items (17B) to (20B), for the treatment and / or prevention of cancer.

  (22B) A method for preventing or treating cancer, comprising administering the compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

  (23B) A compound according to any one of items ((1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof, for the manufacture of a therapeutic and / or prophylactic agent for cancer. use.

  (24B) The compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof for the treatment and / or prevention of cancer.

  (25B) A TTK inhibitor comprising the compound according to any one of items ((1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

  (26B) An anticancer agent comprising the compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

  (27B) A therapeutic agent for immune system diseases comprising the compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

  (28B) An immunosuppressant comprising the compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

  (29B) An autoimmune disease therapeutic agent comprising the compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

  (30B) A method, system, apparatus, kit or the like for producing the compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

  (31B) Method, system, apparatus, kit, etc. for preparing a pharmaceutical composition containing a compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof .

  (32B) A method, system, apparatus, kit or the like using the compound according to any one of items (1B) to (16B), a pharmaceutically acceptable salt thereof, or a solvate thereof.

  (33B) A method for preventing or treating cancer, comprising administering the pharmaceutical composition having TTK inhibitory activity according to item (19B).

  Accordingly, these and other advantages of the invention will be apparent upon reading the following detailed description.

  The present invention provides an effective inhibitor of TTK protein kinase and thus provides an effective medicament for diseases, disorders or conditions related to TTK such as cancer.

  The present invention will be described below with reference to the best mode. Throughout this specification, it should be understood that the singular forms also include the plural concept unless specifically stated otherwise. Therefore, it is understood that singular modifiers (for example, articles such as “a”, “an”, “the” in the case of English, etc.) also include the plural concept unless otherwise stated. Should be. In addition, it is to be understood that the terms used in the present specification are used in the meaning normally used in the above field unless otherwise specified. Thus, unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification, including definitions, will control.

  The meaning of each term used in this specification will be described below. In the present specification, each term is used in a unified meaning, and is used in the same meaning when used alone or in combination with other terms.

  Abbreviations used herein are listed below.


  In the present specification, “halogen” includes fluorine, chlorine, bromine and iodine.

  In the present specification, “alkyl” includes a linear or branched alkyl group having 1 to 10 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, and sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like. For example, alkyl having 1 to 6 or 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, Neopentyl, n-hexyl, isohexyl can be mentioned.

  In the present specification, “alkenyl” includes linear or branched alkenyl having 2 to 8 carbon atoms having one or more double bonds in the above “alkyl”. 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 3-methyl-2-butenyl and the like.

  In the present specification, “alkynyl” includes linear or branched alkynyl having 2 to 8 carbon atoms having one or more triple bonds in the above “alkyl”, and includes, for example, ethynyl, Examples include propynyl and butynyl. Furthermore, it may have one or more double bonds.

  In the present specification, “cycloalkyl” includes a cyclic saturated hydrocarbon group having 3 to 15 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and bridged cyclic hydrocarbon. Group, spiro hydrocarbon group and the like. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and a bridged cyclic hydrocarbon group.

  In the present specification, the “bridged cyclic hydrocarbon group” refers to hydrogen from an aliphatic ring having 5 to 12 carbon atoms in which two or more rings share two or more atoms. Includes groups that can be removed. Specifically, bicyclo [2.1.0] pentyl, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octyl and bicyclo [3.2.1] octyl, tricyclo [2.2. 1.0] heptyl, bicyclo [3.3.1] nonane, 1-adamantyl, 2-adamantyl and the like.

  In the present specification, the “spirohydrocarbon group” includes a group formed by removing one hydrogen from a ring in which two hydrocarbon rings share one carbon atom. Specific examples include spiro [3.4] octyl.

  In the present specification, “cycloalkenyl” includes a cyclic unsaturated aliphatic hydrocarbon group having 3 to 7 carbon atoms, and examples thereof include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, and cycloheptenyl. Cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl. Cycloalkenyl also includes bridged cyclic hydrocarbon groups and spiro hydrocarbon groups having an unsaturated bond in the ring.

  In the present specification, “aryl” includes a monocyclic or condensed aromatic hydrocarbon ring. This may be condensed with the above “cycloalkyl” at all possible positions. Whether aryl is a single ring or a fused ring, it can be attached at all possible positions. For example, phenyl, 1-naphthyl, 2-naphthyl, anthryl, tetrahydronaphthyl and the like can be mentioned. Examples include phenyl, 1-naphthyl and 2-naphthyl. An example is phenyl.

  In the present specification, the “aromatic hydrocarbon ring” includes an aromatic 5- to 8-membered ring containing only a carbon atom in the ring or a ring in which two or more of them are condensed. The monocyclic aromatic hydrocarbon ring includes a ring derived from a 6-membered aromatic hydrocarbon ring and optionally having a bond at any substitutable position. The condensed aromatic hydrocarbon ring has a bond at any substitutable position where the 6-membered aromatic hydrocarbon ring is condensed with 1 to 4 6-membered aromatic hydrocarbon rings. Includes an optional ring. For example, a 6-membered aromatic hydrocarbon ring is mentioned. Examples of the aromatic hydrocarbon ring include a benzene ring, a naphthalene ring, an anthracene ring, and a tetrahydronaphthalene ring. For example, a benzene ring and a naphthalene ring are mentioned.

  In the present specification, the “non-aromatic hydrocarbon ring” includes a non-aromatic 3- to 8-membered ring containing only carbon atoms in the ring or a ring in which two or more thereof are condensed. The monocyclic non-aromatic hydrocarbon ring includes a group derived from a 3- to 8-membered non-aromatic hydrocarbon ring and optionally having a bond at any substitutable position. A fused non-aromatic hydrocarbon ring is any substitutable position where a 5- to 8-membered non-aromatic hydrocarbon ring is fused with 1 to 4 5- to 8-membered non-aromatic hydrocarbon rings Includes a group which may have a bond. If it is non-aromatic, it may be saturated or unsaturated. For example, a 5-6 membered non-aromatic hydrocarbon ring is mentioned. Examples of the non-aromatic hydrocarbon ring include a cyclopropane ring, a cyclobutane ring, a cyclopentane ring, a cyclohexane ring, a cycloheptane ring, a cyclooctane ring, a cyclopropene ring, a cyclobutene ring, a cyclopentene ring, a cyclohexene ring, and a cycloheptene ring. Can be mentioned. Examples thereof include a cyclopentane ring, a cyclohexane ring, a cyclopentene ring, and a cyclohexene ring.

  In the present specification, the “heteroaryl” includes an optionally selected 5- to 8-membered aromatic hydrocarbon ring containing at least one oxygen atom, sulfur atom, and / or nitrogen atom in the ring. This may be condensed with the above “cycloalkyl”, the above “aryl”, the following “heterocyclyl”, or other heteroaryl at all possible positions. Whether the heteroaryl is a single ring or a fused ring, it can be attached at all possible positions. For example, pyrrolyl (eg, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), furyl (eg, 2-furyl, 3-furyl), thienyl (eg, 2-thienyl, 3-thienyl), imidazolyl (eg, 2 -Imidazolyl, 4-imidazolyl), pyrazolyl (eg 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), isothiazolyl (eg 3-isothiazolyl), isoxazolyl (eg 3-isoxazolyl), oxazolyl (eg 2-oxazolyl) , 4-oxazolyl, 5-oxazolyl), thiazolyl (eg 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (eg 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrazinyl (eg 2- Pyrazinyl), pyrimidinyl (eg 2-pyrimidinyl) , 4-pyrimidinyl), pyridazinyl (eg, 3-pyridazinyl), tetrazolyl (eg, 1H-tetrazolyl), oxadiazolyl (eg, 1,3,4-oxadiazolyl), thiadiazolyl (eg, 1,3,4-thiadiazolyl), Indolizinyl (eg, 2-indolidinyl, 6-indolidinyl), isoindolyl (eg, 2-isoindolyl), indolyl (eg, 1-indolyl, 2-indolyl, 3-indolyl), indazolyl (eg, 3-indazolyl), purinyl ( For example, 8-purinyl), quinolidinyl (eg, 2-quinolidinyl), isoquinolyl (eg, 3-isoquinolyl), quinolyl (eg, 2-quinolyl, 5-quinolyl), phthalazinyl (eg, 1-phthalazinyl), naphthyridinyl (Eg, 2-naphthyridinyl), quinazolinyl (eg, 2-quinazolinyl), cinnolinyl (eg, 3-cinnolinyl), pteridinyl (eg, 2-pteridinyl), carbazolyl (eg, 2-carbazolyl, 4-carbazolyl), phenant Lydinyl (eg 2-phenanthridinyl, 3-phenanthridinyl), acridinyl (eg 1-acrinidyl, 2-acrinidyl), dibenzofuranyl (eg 1-dibenzofuranyl, 2-dibenzofuranyl) ), Benzimidazolyl (eg, 2-benzimidazolyl), benzoisoxazolyl (eg, 3-benzoisoxazolyl), benzoxazolyl (eg, 2-benzoxazolyl), benzooxadiazolyl (eg, 4-Benzoxadiazolyl), benzoiso Thiazolyl (eg 3-benzoisothiazolyl), benzothiazolyl (eg 2-benzothiazolyl), benzofuryl (eg 3-benzofuryl), benzothienyl (eg 2-benzothienyl), dibenzothienyl (eg 2-dibenzothienyl) ), Benzodioxolyl (for example, 1,3-benzodioxolyl) and the like.

  In the present specification, “heterocyclyl” may contain 1 to 4 oxygen atoms, sulfur atoms, and / or nitrogen atoms in the ring, and has a bond at any substitutable position. Non-aromatic heterocycles which may be optionally included. Moreover, such a non-aromatic heterocyclic ring may be further bridge | crosslinked with a C1-C4 alkyl chain, a non-aromatic heterocyclic ring (a 5-6 membered ring is mentioned) and an aromatic hydrocarbon ring ( For example, a benzene ring) may be condensed. If it is non-aromatic, it may be saturated or unsaturated. For example, it is a 5- to 8-membered ring. For example, pyrrolinyl (eg, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl), pyrrolidinyl (eg, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl), pyrrolidinone, imidazolinyl (eg, 1-imidazolinyl, 2-imidazolinyl, 4-imidazolinyl), imidazolidinyl (eg 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl), imidazolidinone, pyrazolinyl (eg 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl), pyrazolidinyl (eg 1-pyrazolidinyl) 3-pyrazolidinyl, 4-pyrazolidinyl), piperidinone, piperidino, piperidinyl (eg 2-piperidinyl, 3-piperidinyl, 4-piperidinyl), piperazinyl (eg 1-pipe Jiniru, 2-piperazinyl), piperazinone, morpholinyl (e.g., 2-morpholinyl, 3-morpholinyl), morpholino, tetrahydropyranyl, tetrahydrofuranyl, and the like.

  In the present specification, “saturated heterocyclyl” is a ring having no unsaturated bond (double bond) in the above-mentioned “heterocyclyl”, and has a bond at any substitutable position. The non-aromatic heterocyclic ring which may have is included. Further, such a non-aromatic heterocyclic ring may be further bridged with an alkyl chain having 1 to 4 carbon atoms, such as a non-aromatic heterocyclic ring (including a 5- to 6-membered ring) or a non-aromatic hydrocarbon ring. May be condensed. For example, it is a 5- to 8-membered ring. For example, pyrrolidinyl (eg, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl), pyrrolidinone, imidazolidinyl (eg, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl), imidazolidinone, pyrazolidinyl (eg, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl), piperidinone, piperidino, piperidinyl (eg 2-piperidinyl, 3-piperidinyl, 4-piperidinyl), piperazinyl (eg 1-piperazinyl, 2-piperazinyl), piperazinone, morpholinyl (eg 2 -Morpholinyl, 3-morpholinyl), morpholino, tetrahydropyranyl, tetrahydrofuranyl and the like.

  In the present specification, the “aromatic heterocycle” is an arbitrarily selected aromatic 5- to 8-membered ring containing at least one oxygen atom, sulfur atom and / or nitrogen atom in the ring, or 2 Includes rings fused at least. The monocyclic aromatic heterocycle includes a ring derived from a 5- to 8-membered aromatic hydrocarbon ring which may contain 1 to 4 oxygen, sulfur and / or nitrogen atoms in the ring. . The monocyclic aromatic heterocycle may have a bond at any substitutable position. The condensed aromatic heterocyclic ring has 1 to 4 5- to 5-membered aromatic hydrocarbon rings which may contain 1 to 4 oxygen atoms, sulfur atoms and / or nitrogen atoms in the ring. Includes a ring fused to an 8-membered aromatic hydrocarbon ring or other 5- to 8-membered aromatic heterocycle. The fused aromatic heterocyclic ring may have a bond at any substitutable position. For example, a 5-6 membered aromatic heterocyclic ring is mentioned. Examples of the aromatic heterocycle include pyrrole ring, furan ring, thiophene ring, imidazole ring, pyrazole ring, isothiazole ring, isoxazole ring, oxazole ring, thiazole ring, pyridine ring, pyrazine ring, pyrimidine ring, pyridazine ring, tetrazole Ring, oxadiazole ring, thiadiazole ring, indolizine ring, isoindole ring, indole ring, indazole ring, purine ring, quinolidine ring, isoquinoline ring, quinoline ring, phthalazine ring, naphthyridine ring, quinazoline ring, cinnoline ring , Pteridine ring, carbazole ring, phenanthridine ring, acridine ring, dibenzofuran ring, benzimidazole ring, benzisoxazole ring, benzoxazole ring, benzoxazole ring, benzoisothiazole ring, benzothiazole ring, benzoph Down ring, benzothiophene ring, dibenzothiophene ring, such benzodioxole ring. Examples thereof include a thiophene ring, a pyridine ring, a furan ring, a thiazole ring, an oxazole ring, and a pyrimidine ring.

  In the present specification, the “non-aromatic heterocyclic ring” is a non-aromatic 5- to 8-membered ring containing at least one oxygen atom, sulfur atom and / or nitrogen atom in the ring, Includes two or more condensed rings. For example, pyrroline ring, pyrrolidine ring, pyrrolidinone ring, imidazoline ring, imidazolidine ring, pyrazoline ring, pyrazolidine ring, piperidinone ring, piperidine ring, piperazine ring, piperazinone ring, morpholine ring, tetrahydropyran ring, tetrahydrofuran ring, dihydropyran ring, And dihydrofuran ring. Examples thereof include a dihydropyran ring, a tetrahydropyran ring, a dihydrofuran ring, and a tetrahydrofuran ring.

  As used herein, “acyl” refers to formyl, substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl, substituted or unsubstituted cycloalkylcarbonyl, substituted or unsubstituted cycloalkenylcarbonyl, substituted or unsubstituted Including substituted arylcarbonyl, substituted or unsubstituted heteroarylcarbonyl, substituted or unsubstituted heterocyclylcarbonyl.

In the present specification, “fused pyrazole”, “fused pyrimidine”, and “fused pyridine” mean that pyrazole, pyrimidine, and pyridine are the above “cycloalkyl”, the above “aryl”, the above “heterocyclyl”, or Included are fused rings fused at all possible positions with the “heteroaryl”. Examples of the condensed pyrazole include 4,6-dihydro-1H-thieno [3,4-c] pyrazole. As the condensed pyrimidine, for example, 6,7,8,9-
And tetrahydro-5H-pyrimido [4,5-d] azepine. Examples of the condensed pyridine include pyrido [3,2-b] pyrazine, 1,8-naphthyridine, quinoline and the like.

  In the present specification, “alkoxy” means, for example, methyloxy, ethyloxy, n-propyloxy, isopropyloxy, n-butyloxy, isobutyloxy, sec-butyloxy, tert-butyloxy, n-pentyloxy, isopentyloxy, Examples include 2-pentyloxy, 3-pentyloxy, n-hexyloxy, isohexyloxy, 2-hexyloxy, 3-hexyloxy, n-heptyloxy, n-octyloxy and the like. For example, C1-C6 alkoxy is mentioned. Moreover, C1-C4 alkoxy is mentioned, for example. In particular, when a carbon number is specified, it means “alkoxy” having a carbon number within the range.

In the present specification, “substituted or unsubstituted alkyl”, “substituted or unsubstituted alkenyl”, “substituted or unsubstituted alkynyl”, “substituted or unsubstituted cycloalkyl”, “substituted or unsubstituted cycloalkenyl” ”,“ Substituted or unsubstituted aryl ”,“ substituted or unsubstituted heteroaryl ”,“ substituted or unsubstituted heterocyclyl ”,“ substituted or unsubstituted saturated heterocyclyl ”“ substituted or unsubstituted alkoxy ” , "Substituted or unsubstituted acyl", "substituted or unsubstituted alkoxycarbonyl", "substituted or unsubstituted piperidine", "substituted or unsubstituted thiophene", "substituted or unsubstituted tetrahydropyran", "substituted Or “unsubstituted fused pyrimidine”, “substituted or unsubstituted fused pyridine” "Substituted or unsubstituted tetrahydrofuran", "Substituted or unsubstituted aromatic hydrocarbon ring", "Substituted or unsubstituted non-aromatic hydrocarbon ring", "Substituted or unsubstituted aromatic heterocycle", "Substituted Or “unsubstituted non-aromatic heterocycle”, “substituted or unsubstituted pyrazolyl”, “substituted or unsubstituted imidazolyl”, “substituted or unsubstituted oxazolyl”, “substituted or unsubstituted oxadiazolyl”, “substituted or “Unsubstituted pyrazole”, “substituted or unsubstituted pyridine”, “substituted or unsubstituted piperidinyl”, “substituted or unsubstituted cyclopropyl”, “substituted sulfinyl”, “substituted or unsubstituted morpholinyl”, or “ Examples of the substituent in the “substituted sulfonyl” include hydroxy, carboxy, halogen, halo. Emissions alkyl (eg: CF 3, CH 2 CF 3 , CH 2 CCl 3), nitro, nitroso, cyano, alkyl (e.g. methyl, ethyl, isopropyl, tert- butyl), alkenyl (e.g. vinyl), alkynyl ( Example: ethynyl), cycloalkyl (eg, cyclohexyl, cyclopropyl, adamantyl), cycloalkylalkyl (eg, cyclohexylmethyl, adamantylmethyl), cycloalkenyl (eg, cyclopropenyl), aryl (eg, phenyl, naphthyl), aryl Alkyl (eg benzyl, phenethyl), heteroaryl (eg: pyrazolyl, pyridyl, furyl), heteroarylalkyl (eg: pyridylmethyl), heterocyclyl (eg: piperidyl, tetrahydropyranyl), heterocyclylalkyl (eg : Morpho Rumechiru), alkoxy (e.g. methoxy, ethoxy, propoxy, butoxy), halogenated alkoxy (e.g. OCF 3), alkenyloxy (e.g. vinyloxy, allyloxy), aryloxy (e.g. phenyloxy), alkyloxycarbonyl (eg : Methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl), arylalkyloxy (eg, benzyloxy), unsubstituted amino, substituted amino [eg: alkylamino (eg: methylamino, ethylamino, dimethylamino), acylamino (eg, : Acetylamino, benzoylamino), arylalkylamino (eg, benzylamino, tritylamino), hydroxyamino], alkylaminoalkyl (eg, diethylaminomethyl), sulfamoyl, oxo, carbamo It is selected from the group consisting of a Le. It may be substituted with 1 to 4 such substituents.

  In the present specification, the substituents of “substituted or unsubstituted amino”, “substituted amino” and “substituted or unsubstituted carbamoyl” include alkyl, alkenyl, aryl, heteroaryl, alkylcarbonyl, arylcarbonyl, heteroaryl. Carbonyl, heterocyclylcarbonyl, alkyloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, heterocyclyloxycarbonyl, sulfamoyl, carbamoyl, alkylsulfonyl, cycloalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, heterocyclylsulfonyl, alkyl Sulfinyl, cycloalkylsulfinyl, arylsulfinyl, heteroarylsulfinyl, heterocyclylsulfinyl, hydroxy , Mercapto, sulfino, sulfo, and amino and the like.

  In the present specification, the “substituted or unsubstituted alkoxy” and the alkyl moiety of “halogenated alkyl” mean the above “alkyl”.

  In the present specification, the alkoxy moiety of “substituted or unsubstituted alkoxy”, “substituted or unsubstituted alkoxycarbonyl”, and “halogenated alkoxy” means the above “alkoxy”.

  Examples of the pharmaceutically acceptable salt of the compound of the present invention include the following salts.

  Examples of basic salts include alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as calcium salt and magnesium salt; ammonium salt; trimethylamine salt, triethylamine salt, dicyclohexylamine salt, ethanolamine salt, diethanolamine salt Aliphatic amine salts such as triethanolamine salt, procaine salt, meglumine salt, diethanolamine salt or ethylenediamine salt; aralkylamine salts such as N, N-dibenzylethylenediamine salt and venetamine salt; pyridine salt, picoline salt, quinoline salt, Heterocyclic aromatic amine salts such as isoquinoline salt; tetramethylammonium salt, tetraethylammonium salt, benzyltriethylammonium salt, benzyltriethylammonium salt, benzyltributylammonium And quaternary ammonium salts such as dimethyl salt, methyl trioctyl ammonium salt and tetrabutyl ammonium salt; and basic amino acid salts such as arginine salt and lysine salt.

  Examples of the acid salt include inorganic acid salts such as hydrochloride, sulfate, nitrate, phosphate, carbonate, bicarbonate, perchlorate; acetate, propionate, lactate, maleate, Organic acid salts such as fumarate, tartrate, malate, citrate, ascorbate; sulfonates such as methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate; Examples include acidic amino acids such as aspartate and glutamate.

  In the present specification, the solvate means a solvate of the compound of the present invention or a pharmaceutically acceptable salt thereof, and examples thereof include alcohol (eg, ethanol) solvate and hydrate. Examples of the hydrate include monohydrate, dihydrate and the like.

  Furthermore, one or more hydrogen, carbon or other atoms of the compound of formula (I) may be replaced with isotopes of hydrogen, carbon or other atoms. Compounds of formula (I) include all radiolabeled forms of compounds of formula (I). Such “radiolabeled”, “radiolabeled” and the like of the compounds of formula (I) are each encompassed by the present invention and are useful as research and / or diagnostic tools in metabolic pharmacokinetic studies and binding assays. . It is also useful as a pharmaceutical product.

Examples of isotopes that can be incorporated into the compound of formula (I) of the present invention include 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, and 35 S, respectively. , 18 F, and 36 Cl include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine. The radiolabeled compound of the present invention can be prepared by methods well known in the art. For example, a tritium labeled compound of formula (I) can be prepared by introducing tritium into a specific compound of formula (I) by, for example, catalytic dehalogenation reaction using tritium. This method involves reacting a compound of formula (I) with a suitably halogen-substituted precursor and tritium gas in the presence of a suitable catalyst, for example Pd / C, in the presence or absence of a base. May be. For suitable methods for preparing other tritium labeled compounds, reference may be made to the document Isotopes in the Physical and Biomedical Sciences, Vol. 1, Labeled Compounds (Part A), Chapter 6 (1987). 14 C-labeled compounds can be prepared by using raw materials having 14 C carbon.

(Preferred pyridine and pyrimidine derivative compounds of the present invention)
In the compound, pharmaceutically acceptable salt or solvate or prodrug thereof (ester, amide, etc.) included in the pharmaceutical composition having TTK inhibitory activity, the above substituents are described herein. Any substituent can be used, and for example, any preferable substituent exemplified in the means for solving the problem can be used.

  When considering the pyridine and pyrimidine derivatives of the present invention, the following factors can be considered.

  Preferred embodiments of the invention are exemplified below as (A1) to (A12), (B1) to (B6), (C1) to (C13), and (D1) to (D6). Unless otherwise specified, each symbol has the same meaning as described above.

(A1)
Formula (I):

In
X includes ═C (R 4 ) — or ═N—.

For example, X includes ═C (R 4 ) —.

  For example, X includes ═CH—.

  For example, X may be = N-.

A includes a substituted or unsubstituted aromatic hydrocarbon ring, a substituted or unsubstituted aromatic heterocyclic ring (however, a substituted or unsubstituted pyrazole or condensed pyrazole (for example, 4,6-dihydro-1H-thieno [3 , 4-c] pyrazole), substituted or unsubstituted non-aromatic hydrocarbon rings or substituted or unsubstituted non-aromatic heterocycles.

  For example, A includes a substituted or unsubstituted aromatic hydrocarbon ring, a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyrazole or condensed pyrazole and substituted or unsubstituted thiophene), Examples thereof include a substituted or unsubstituted non-aromatic hydrocarbon ring or a substituted or unsubstituted non-aromatic heterocyclic ring.

  For example, A includes a substituted or unsubstituted aromatic hydrocarbon ring.

  For example, in A, the formula (III):

As the group represented by
Formula (IV):

The group shown by these is mentioned.

Examples of R 1 include hydrogen, substituted or unsubstituted alkyl, a group represented by the formula: —NR 1A R 1A ′ , or a group represented by the formula: —OR 1B .

For example, R 1 includes a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B .

For example, R 1 includes a group represented by the formula: —NHR 1A ′ or a group represented by the formula: —OR 1B .

For example, R 1 includes a group represented by the formula: —NHR 1A ′ .

For example, R 1 includes a group represented by the formula: —OR 1B .

Here, R 1A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cyclo Examples include alkyl or substituted or unsubstituted saturated heterocyclyl.

Here, R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl Or a substituted or unsubstituted saturated heterocyclyl is mentioned.

Here, R 1B represents substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl Or a substituted or unsubstituted saturated heterocyclyl is mentioned.

For example, R 1 includes a group represented by the formula: —NHR 1A ′ , where R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted saturated heterocyclyl. Is mentioned.

For example, R 1 includes a group represented by the formula: —OR 1B , and R 1B includes substituted or unsubstituted cycloalkyl.

R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted Heterocyclyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino, halogen, carboxy or hydrogen.

For example, R 2 includes cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted Examples include substituted heterocyclyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino or carboxy.

For example, R 2 includes cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbamoyl, substituted or unsubstituted Examples include substituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino or carboxy.

For example, R 2, include cyano.

Or R 1 and R 2 together with adjacent carbon atoms,
Formula (II):

You may form group shown by these.

Where
R 1A ″ and R 2A ″ each independently represent substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, Substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl.

For example, R 1A ″ and R 2A ″ each independently include substituted or unsubstituted alkyl or substituted or unsubstituted cycloalkyl.

R a and R b each independently include hydrogen or substituted or unsubstituted alkyl.

    As n, the integer of 0-3 is mentioned.

    For example, as n, the integer of 0-2 is mentioned.

R 3 includes hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or halogen.

For example, R 3 includes hydrogen.

For example, R 3 includes substituted or unsubstituted alkyl.

R 4 includes hydrogen or halogen.

For example, R 4 includes hydrogen.

R 5A and R 5B are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, substituted or unsubstituted acyl, substituted or unsubstituted alkoxy, substituted or Examples include unsubstituted carbamoyl, a group represented by the formula: —SO 2 —R ′, a group represented by the formula: —SO—R ′, or a group represented by the formula: —SR ′.

For example, R 5A includes substituted or unsubstituted heteroaryl or substituted or unsubstituted alkenyl.

For example, R 5A includes substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted alkenyl.

For example, R 5B includes hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

    Here, R ′ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted Substituted heterocyclyl is mentioned.

Provided that (i) X is = C (R 4 )-, and A is substituted or unsubstituted piperidine, substituted or unsubstituted thiophene, substituted or unsubstituted tetrahydropyran, substituted or unsubstituted condensed pyrimidine (for example, 6,7,8,9-tetrahydro-5H-pyrimido [4,5-d] azepine), substituted or unsubstituted fused pyridine (eg, pyrido [3,2-b] pyrazine, 1,8-naphthyridine, Quinoline) or substituted or unsubstituted tetrahydrofuran, R 2 is cyano.

However, when (ii) X is = C (R 4 )-, A is a substituted or unsubstituted aromatic hydrocarbon ring, and R 2 is nitro, R 1 is represented by the formula: —NR 1A R It is not a group represented by 1A ′ (where R 1A ′ is phenylethyl) and a group represented by the formula: —OR 1B (where R 1B is methyl).

However, (iii) when X is ═C (R 4 ) — and A is a substituted or unsubstituted non-aromatic hydrocarbon ring, R 1 is a group represented by the formula: —NR 1A R 1A ′ (Wherein R 1A ′ is a substituted or unsubstituted alkyl) and a group represented by the formula: —OR 1B (where R 1B is a substituted or unsubstituted alkyl).

However, (iv) X is ═C (R 4 ) —, A is a substituted or unsubstituted aromatic hydrocarbon ring, R 2 is cyano, and R 1 is represented by the formula: —NR 1A R 1A ′ In which R 1A ′ is substituted or unsubstituted alkyl or a group represented by the formula: —OR 1B (where R 1B is methyl or ethyl), R 3 is hydrogen is there.

However, (v) when X is ═C (R 4 ) — and A is a non-aromatic heterocyclic ring, R 1 is a group represented by the formula: —NR 1A R 1A ′ (where R 1A ' Is not substituted or unsubstituted alkyl).

However, (vi) when X is = C (R 4 )-, the number of hydrogens in R 1 , R 3 and R 4 is 2 or less.

However, (vii) when X is = N-, A is a substituted or unsubstituted aromatic hydrocarbon ring or a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyridine). R 2 is cyano, R 3 is hydrogen, R 1 is a group represented by the formula: —NR 1A R 1A ′ (where R 1A ′ is a substituted or unsubstituted alkyl, substituted or non-substituted Substituted piperidinyl and substituted or unsubstituted cyclopropyl) and not a group of formula: —OR 1B where R 1B is a substituted or unsubstituted alkyl.

However, (viii) when X is = N-, A is a substituted or unsubstituted aromatic hydrocarbon ring or a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyridine). R 2 is cyano, R 3 is hydrogen, and R 5A is not substituted sulfinyl, substituted or unsubstituted carbamoyl, carboxy, substituted or unsubstituted morpholinyl and substituted sulfonyl.

  However, the compounds shown below:

except for.

  The following embodiment may also be an embodiment.

(A2)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X includes ═C (R 4 ) — (where R 4 has the same meaning as the above item (1A) or (1B)).

As R 1 and R 2 , R 1 and R 2 together with adjacent carbon atoms,
Formula (II):

Is formed.

Where
R 1A ″ and R 2A ″ each independently include substituted or unsubstituted alkyl or substituted or unsubstituted cycloalkyl.

  As n, the integer of 0-2 is mentioned.

  A includes a substituted or unsubstituted aromatic hydrocarbon ring.

R 3 includes hydrogen.

(A3)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is a substituted or unsubstituted aromatic hydrocarbon ring,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl;
R 2 is cyano,
R 3 is hydrogen;
R 5A is substituted or unsubstituted heteroaryl or substituted or unsubstituted alkenyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(A4)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted benzene,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl;
R 2 is cyano,
R 3 is hydrogen;
R 5A is substituted or unsubstituted heteroaryl or substituted or unsubstituted alkenyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(A5)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted benzene,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl;
R 2 is cyano,
R 3 is hydrogen;
R 5A is substituted or unsubstituted heteroaryl or substituted or unsubstituted alkenyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(A6)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted benzene,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is substituted or unsubstituted heteroaryl or substituted or unsubstituted alkenyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(A7)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted benzene,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is a substituted or unsubstituted heteroaryl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(A8)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted benzene,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted alkenyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(A9)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted benzene,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
Pyrazolyl or unsubstituted pyrazolyl, wherein R 5A is substituted with C1-C6 alkyl, imidazolyl or unsubstituted imidazolyl substituted with C1-C6 alkyl, oxazolyl or unsubstituted oxazolyl substituted with C1-C6 alkyl, C1- Oxadiazolyl or unsubstituted oxadiazolyl substituted with C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(A10)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted benzene,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(A11)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted benzene,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is substituted or unsubstituted alkoxy.

(A12)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted benzene,
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is alkoxy substituted with cyano or unsubstituted alkoxy.

In (A1) to (A12), A is an unsubstituted (excluding R 5A and R 5B ) aromatic hydrocarbon ring, an unsubstituted (except R 5A and R 5B ) aromatic heterocyclic ring, or unsubstituted non-aromatic hydrocarbon ring (excluding R 5A and R 5B), a non-aromatic heterocycle unsubstituted (except for R 5A and R 5B), benzene include unsubstituted (except for R 5A and R 5B) It is done.

(B1)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted pyridine;
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is a substituted or unsubstituted heteroaryl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(B2)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted pyridine;
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted alkenyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(B3)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted pyridine;
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
Pyrazolyl or unsubstituted pyrazolyl, wherein R 5A is substituted with C1-C6 alkyl, imidazolyl or unsubstituted imidazolyl substituted with C1-C6 alkyl, oxazolyl or unsubstituted oxazolyl substituted with C1-C6 alkyl, C1- Oxadiazolyl or unsubstituted oxadiazolyl substituted with C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(B4)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted pyridine;
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(B5)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted pyridine;
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is substituted or unsubstituted alkoxy.

(B6)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I):
X is = CH-
A is substituted or unsubstituted pyridine;
R 1 is a group represented by the formula: —NHR 1A ′ ;
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 2 is cyano,
R 3 is hydrogen;
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is alkoxy substituted with cyano or unsubstituted alkoxy.

In (B1) to (B6), examples of A include unsubstituted (excluding R 5A and R 5B ) pyridine.

(C1)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

  Formula (I '):

Where
R 1A ′ is substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl;
R 3 is hydrogen or substituted or unsubstituted alkyl;
R 5A is a substituted or unsubstituted heteroaryl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(C2)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is hydrogen or substituted or unsubstituted alkyl;
R 5A is a substituted or unsubstituted heteroaryl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(C3)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is hydrogen;
R 5A is a substituted or unsubstituted heteroaryl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(C4)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is hydrogen;
R 5A is substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted alkenyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(C5)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is hydrogen;
Pyrazolyl or unsubstituted pyrazolyl, wherein R 5A is substituted with C1-C6 alkyl, imidazolyl or unsubstituted imidazolyl substituted with C1-C6 alkyl, oxazolyl or unsubstituted oxazolyl substituted with C1-C6 alkyl, C1- Oxadiazolyl or unsubstituted oxadiazolyl substituted with C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(C6)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is hydrogen;
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(C7)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is hydrogen;
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is substituted or unsubstituted alkoxy.

(C8)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is hydrogen;
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is alkoxy substituted with cyano or unsubstituted alkoxy.

(C9)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is substituted or unsubstituted alkyl,
R 5A is substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted alkenyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(C10)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is substituted or unsubstituted alkyl,
Pyrazolyl or unsubstituted pyrazolyl, wherein R 5A is substituted with C1-C6 alkyl, imidazolyl or unsubstituted imidazolyl substituted with C1-C6 alkyl, oxazolyl or unsubstituted oxazolyl substituted with C1-C6 alkyl, C1- Oxadiazolyl or unsubstituted oxadiazolyl substituted with C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(C11)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is substituted or unsubstituted alkyl,
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl.

(C12)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is substituted or unsubstituted alkyl,
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is substituted or unsubstituted alkoxy.

(C13)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ′):
R 1A ′ is a substituted or unsubstituted cycloalkyl,
R 3 is substituted or unsubstituted alkyl,
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is alkoxy substituted with cyano or unsubstituted alkoxy.

(D1)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

  Formula (I ″):

Where
R 5A is a substituted or unsubstituted heteroaryl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino or substituted or unsubstituted alkyl;
R a and R b are each independently hydrogen,
n is an integer from 0 to 3,
R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl.

(D2)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ″):
R 5A is substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted alkenyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino or substituted or unsubstituted alkyl;
R a and R b are each independently hydrogen,
n is an integer from 0 to 3,
R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl.

(D3)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ″):
Pyrazolyl or unsubstituted pyrazolyl, wherein R 5A is substituted with C1-C6 alkyl, imidazolyl or unsubstituted imidazolyl substituted with C1-C6 alkyl, oxazolyl or unsubstituted oxazolyl substituted with C1-C6 alkyl, C1- Oxadiazolyl or unsubstituted oxadiazolyl substituted with C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl,
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino or substituted or unsubstituted alkyl;
R a and R b are each independently hydrogen,
n is an integer from 0 to 3,
R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl.

(D4)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ″):
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino or substituted or unsubstituted alkyl;
R a and R b are each independently hydrogen,
n is an integer from 0 to 3,
R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl.

(D5)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ″):
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is substituted or unsubstituted alkoxy;
R a and R b are each independently hydrogen,
n is an integer from 0 to 3,
R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl.

(D6)
The definition of each substituent is synonymous with the said item (1A) or (1B) unless there is particular notice.

In general formula (I ″):
R 5A is pyrazolyl or unsubstituted pyrazolyl substituted with C1-C6 alkyl or alkenyl or unsubstituted alkenyl substituted with carbamoyl;
R 5B is alkoxy substituted with cyano or unsubstituted alkoxy;
R a and R b are each independently hydrogen,
n is an integer from 0 to 3,
R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl.

  In another embodiment, the present invention provides a medicament comprising a compound according to any of the above, a pharmaceutically acceptable salt or solvate thereof, or a prodrug (eg, ester, amide) thereof. A composition is provided.

In this specification, “prodrug” and “prodrug compound” have a group that can be chemically or metabolically decomposed, and are pharmaceutically active by hydrolysis, solvolysis, or decomposition under physiological conditions. Is a derivative of the compound of the present invention. Various forms of prodrugs are known in the art. For examples of such prodrug derivatives, the following documents (a) to (f) can be referred to. Prodrugs of compounds of formula (I) are prepared by modifying functional groups present in compounds of formula (I) by a modification method such that the parent compound is released upon cleavage in vivo. For example, prodrugs are compounds of formula (I) wherein the hydroxy, sulfhydryl or amino group in the compound of formula (I) is linked to a group that regenerates the free hydroxy, amino, or sulfhydryl group, respectively, when cleaved in vivo. ). Examples of prodrugs include, but are not limited to, esters of hydroxy functional groups (eg, acetate, formate, and benzoate derivatives), carbamates (eg, N, N-dimethylaminocarbonyl) in compounds of formula (I) Etc.
(A) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and Methods
in Enzymology, Vol. 42.p.309-396, edited by K. Widder, et al. (Academic Press, 1985);
(B) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen;
(C) H. Bundgaard, Chapter 5 “Design and Application of Prodrugs”, by H. Bundgaard p. 113-191 (1991);
(D) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);
(E) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); and (f) N. Kakeya, et al., Chem Pharm Bull, 32, 692 (1984).

An example of one prodrug group is an in vivo cleavable ester group of a pharmaceutically acceptable ester that is cleaved in the human or animal body to yield the parent acid. For example, a prodrug group, together with the carboxy group to which it is attached, is a C 1-6 alkyl ester or C 1-6 cycloalkyl ester, such as methyl, ethyl, propyl, isopropyl, n-butyl or Esters of cyclopentyl; C 1-6 alkoxymethyl esters, such as methoxymethyl esters; C 1-6 alkanoyloxymethyl esters, such as pivaloyloxymethyl esters; phthalidyl esters; C 3-8 cycloalkoxycarbonyloxy C 1 -6 alkyl esters such as 1-cyclohexylcarbonyloxyethyl ester; 1,3-dioxolan-2-ylmethyl ester such as 5-methyl-1,3-dioxolan-2-ylmethyl ester; C 1-6 alkoxy Carbonyloxyethyl ester, for example 1 -Methoxycarbonyloxyethyl ester; aminocarbonylmethyl ester and its mono- or di-N- (C 1-6 alkyl) variants, such as N, N-dimethylaminocarbonylmethyl ester and N-ethylaminocarbonylmethyl ester Pharmaceutically acceptable esters, and pharmaceutically acceptable esters of substituted or unsubstituted heterocyclic groups. In one embodiment, the prodrug has an ester with a C 1-4 alkyl group such as isopropyl or cyclopentyl, or an ester selected from an optionally substituted heterocyclic group such as N-methyltetrahydropyridyl. Can be mentioned.

  The pharmaceutical composition of the present invention comprising any of the specific compounds listed above is also characterized by being a TTK inhibitor. Accordingly, any pharmaceutical composition that exhibits a medicinal effect by being administered to a patient in need of inhibition of TTK is provided.

  In another embodiment, the present invention provides a medicament for the treatment or prevention of cancer or immune disease, comprising any of the specific compounds listed above.

(Production method)
A general method for producing the compound of the present invention is illustrated below. Extraction, purification, and the like may be performed in a normal organic chemistry experiment.

  Below, the manufacturing method of the compound of this invention is described.

  The synthesis of the compound of the present invention can be carried out in consideration of techniques known in the art.

  The raw material compounds are commercially available compounds, those described in Patent Documents 4 to 60 and Non-Patent Documents 7 to 20, and those described in this specification as well as other references cited in this specification. In addition to those described in (1), other known compounds can be used.

  Some of the compounds of the present invention may have tautomers, positional isomers and optical isomers, but the present invention includes all possible isomers and mixtures thereof, including these. To do.

  When obtaining a salt of the compound of the present invention, if the compound of the present invention is obtained in the form of a salt, it can be purified as it is, and if it is obtained in a free form, it can be dissolved in an appropriate organic solvent. Alternatively, it may be suspended and an acid or base is added to form a salt by a conventional method.

  In addition, the compounds of the present invention and pharmaceutically acceptable salts thereof may exist in the form of adducts (hydrates or solvates) with water or various solvents, and these adducts are also included in the present invention. Is included.

  These derivatives are converted and activated in the body and are also referred to herein as “prodrugs”. Examples of prodrugs are understood to include, for example, the above salts and solvates, as well as esters (eg, alkyl esters), amides, and the like.

  Various examples of the compound of the present invention are listed in the Examples, and those skilled in the art can also produce and use compounds not exemplified in the present invention with reference to these.

  The present invention also relates to systems, devices, and kits for producing the compounds of the present invention. It is understood that the constituent requirements of such a system, apparatus, and kit can use those known in the art and can be appropriately designed by those skilled in the art.

(General synthesis method)
A typical method for producing the compound of the present invention is shown in the following scheme. The compounds of the present invention can be produced by the schemes shown below or the methods shown in the examples, but the production methods of the compounds of the present invention are not limited thereto.

  In the general synthesis methods 1 to 11, preferred ones among them have been presented, but are not particularly limited thereto.

(General synthesis method 1: When R 1 is amino or alkoxy)
Scheme 1

(In the formula, each symbol has the same meaning as the above item (1A) or (1B), and X represents a leaving group (halogen, OTf, etc.). Here, “Tf” represents a trifluoromethanesulfonyl group.)
The compound represented by the formula (1-3) and the formula (1-4) can be produced from the compound represented by the formula (1-1) in two steps.

  As the compounds represented by formula (1-1) and formula (1-5), known compounds may be used, or compounds derived from known compounds by a conventional method may be used. The compound represented by the formula (1-5) can also be produced by the method shown in Scheme 7.

The compound represented by the formula (1-2) can be produced by reacting the compound represented by the formula (1-1) with the compound represented by the formula (1-5). In other words, in the presence of an organic base such as DIEA, NMP, DMF, ether solvents (eg, THF, dioxane, etc.), and alcohol solvents (eg, ethanol, propanol, etc.) should be performed at a temperature of 80 ° C. or higher. Thus, the corresponding compound represented by the formula (1-2) can be produced. In addition, this reaction involves palladium catalysts (eg Pd (OAc) 2 , Pd 2 (dba) 3 etc.), phosphine-based ligands (eg BINAP, Xantphos etc.) and bases (eg cesium carbonate, potassium carbonate etc.) ) In the presence of a solvent such as dioxane and toluene.

The compound represented by the formula (1-3) can be produced by reacting the compound represented by the formula (1-2) with the compound represented by the formula (NHR 1A R 1A ′ ). That is, it corresponds to the formula (1-2) by carrying out a compound represented by the formula (NHR 1A R 1A ′ ) of 2 equivalents or more in a solvent such as NMP and DMF at a temperature of 100 ° C. or higher. A compound represented by the formula (1-3) can be produced. When the reaction proceeds slowly or does not proceed, the temperature can be raised to about 250 ° C. using a microwave reaction apparatus.

The compound represented by the formula (1-4) can be produced by reacting the compound represented by the formula (1-2) and the formula (R 1B OH). In other words, for the formula (1-2), the compound represented by the formula (R 1B OH) is carried out in the presence of sodium hydride in a solvent such as NMP and DMF at a temperature of 80 ° C. or higher. A compound represented by the formula (1-4) can be produced. When the reaction proceeds slowly or does not proceed, the temperature can be raised to about 250 ° C. using a microwave reaction apparatus.

(General synthesis method 2: When R 1 is an alkyl group)
Scheme 2

(Wherein each symbol has the same meaning as the above item (1A) or (1B), X represents a leaving group (halogen, OTf, etc.), where “Tf” represents a trifluoromethanesulfonyl group. (The compound represented by (2-3) means the corresponding boronic acid or boronic ester.)
The compound represented by the formula (2-2) can be produced from the compound represented by the formula (1-1) in two steps.

  The compound represented by the formula (1-2) is synonymous with the compound shown in Scheme 1 and can be produced by the method shown in Scheme 1, but a known compound may be used or from a known compound A compound derived by a conventional method may be used.

The compound represented by the formula (2-1) can be produced by a Suzuki coupling reaction between the compound represented by the formula (1-2) and the formula (2-3). That is, in the presence of a palladium catalyst (eg, Pd (PPh 3 ) 4 , Pd 2 (dba) 3 ) and a base (eg, sodium carbonate, potassium carbonate), NMP, DMF, an ether solvent (eg, THF, dioxane) Etc.) and an alcohol solvent (eg, ethanol, propanol, etc.) at a temperature of 50 ° C. or higher, the corresponding compound represented by the formula (2-1) can be produced. This reaction is not limited to these conditions, and a known method can be applied.

  The compound represented by the formula (2-2) can be produced by a hydrogenation reaction to an olefin. In other words, in the presence of palladium carbon, NMP, DMF, ethyl acetate, ether solvents (eg, THF, dioxane, etc.), alcohol solvents (eg, ethanol, propanol, etc.), or a mixed solvent thereof under hydrogen atmosphere. By doing so, the corresponding compound represented by the formula (2-2) can be produced. This reaction is not limited to these conditions, and a known method can be applied.

(General synthesis method 3: when R 1 is an alkyl group)
Scheme 3

(In the formula, each symbol has the same meaning as the above item (1A) or (1B), and X represents a leaving group (halogen, OTf, etc.). Here, “Tf” represents a trifluoromethanesulfonyl group.)
The compound represented by the formula (3-1) can be produced from the compound represented by the formula (1-2).

The compound represented by the formula (3-1) can be produced by Negishi coupling reaction between the compound represented by the formula (1-2) and the compound represented by the formula (R 1 -ZnX: X = halogen). That is, the corresponding compound represented by the formula (3-1) can be produced by carrying out in the presence of a palladium catalyst (eg, Pd (PPh 3 ) 4 ) in a THF solvent at a temperature of 50 ° C. or higher. This reaction is not limited to these conditions, and a known method can be applied.

(General synthesis method 4: R 2 = NO 2 or substituted or unsubstituted acyl)
Scheme 4

(In the formula, each symbol has the same meaning as the above item (1A) or (1B), and X represents a leaving group (halogen, OTf, etc.). Here, “Tf” represents a trifluoromethanesulfonyl group.)
The compound represented by the formula (4-5) and the formula (4-5) can be produced from the compound represented by the formula (4-1) in two steps.

  As the compound represented by the formula (4-1), a known compound may be used, or a compound derived from a known compound by a conventional method may be used.

The compound represented by the formula (4-2) can be produced by reacting the compound represented by the formula (4-1) with the compound represented by the formula (NHR 1A R 1A ′ ). That is, when the compound represented by the formula (NHR 1A R 1A ′ ) of 2 equivalents or more with respect to the formula (4-1) is carried out in a solvent such as NMP and DMF at room temperature, the corresponding formula (4- The compound shown in 2) can be produced. When the reaction proceeds slowly or does not proceed, the temperature can be raised to about 100 ° C.

The compound represented by the formula (4-3) can be produced by reacting the compound represented by the formula (4-1) and the formula (R 1B OH). In other words, for the formula (4-1), the compound represented by the formula (R 1B OH) is carried out in the presence of sodium hydride in a solvent such as NMP and DMF at a temperature of 80 ° C. or higher. A compound represented by the formula (4-3) can be produced. When the reaction proceeds slowly or does not proceed, the temperature can be raised to about 100 ° C.

The compound represented by formula (4-4) or formula (4-5) is obtained by reacting the compound represented by formula (4-2) or formula (4-3) with the compound represented by formula (1-5). Can be manufactured. That is, in the presence of a palladium catalyst (eg, Pd (OAc) 2 , Pd 2 (dba) 3, etc.), a phosphine-based ligand (eg, BINAP, Xantphos, etc.), and a base (eg, cesium carbonate, potassium carbonate), A compound represented by the formula (4-4) or the formula (4-5) can be produced by carrying out the reaction at a temperature of 80 ° C. or higher in a solvent such as dioxane and toluene.

(General synthesis method 5: when R 2 is substituted or unsubstituted aryl, heteroaryl, alkenyl, or alkynyl)
Scheme 5

(In the formula, each symbol has the same meaning as the above item (1A) or (1B), and X represents a leaving group (halogen, OTf, etc.). Here, “Tf” represents a trifluoromethanesulfonyl group.)
The compound represented by formula (5-4) can be produced from the compound represented by formula (5-1) in three steps.

X 1 shown in Scheme 5 is a halogen atom or an OTf group, preferably a fluorine or chlorine atom. X 2 is a halogen atom or an OTf group, preferably a bromine or iodine atom. X is as defined above. As the compound represented by the formula (5-1) or the formula (R 2 -X), a known compound may be used, or a compound derived from a known compound by a conventional method may be used. The compound represented by the formula (R 1 -H) is synonymous with the compound represented by the formula (NHR 1A R 1A ′ ) or the formula (R 1B OH) described above.

The compound represented by the formula (5-2) can be produced by reacting the compound represented by the formula (5-1) and the formula (R 1 -H). This reaction can be carried out under the same conditions as in the production method of formula (1-3) or formula (1-4).

The compound represented by the formula (5-3) can be produced by a Suzuki coupling reaction between the compound represented by the formula (5-2) and the compound represented by the formula (R 2 -X). That is, in the presence of a palladium catalyst (eg, Pd (PPh 3 ) 4 , Pd 2 (dba) 3 ) and a base (eg, sodium carbonate, potassium carbonate), NMP, DMF, an ether solvent (eg, THF, dioxane) Etc.) and an alcohol solvent (eg, ethanol, propanol, etc.) at a temperature of 50 ° C. or higher, the corresponding compound represented by the formula (5-3) can be produced. This reaction is not limited to these conditions, and a known method can be applied.

  The compound represented by the formula (5-4) can be produced by reacting with the compound represented by the formula (1-5). This reaction can be carried out under the same conditions as in the production method of formula (1-2).

(General synthesis method 6: In the case of pyrimidine derivatives)
Scheme 6

(Wherein each symbol has the same meaning as the above item (1A) or (1B), R represents a lower (eg, C1-C6) alkyl group, and X represents a leaving group (halogen, OTf, etc.). Here, “Tf” represents a trifluoromethanesulfonyl group.)
The compound represented by formula (6-6) can be produced from the compounds represented by formula (6-1) and formula (6-2) in four steps.

As the compound represented by the formula (6-1) or the formula (6-2), a known compound may be used, or a compound derived from a known compound by a conventional method may be used. The compounds represented by the formula (1-5) and the formula (R 1 -H) are synonymous with the compounds described above.

  The compound represented by the formula (6-3) can be produced by reacting a compound represented by the formula (6-1) or a salt thereof with a compound represented by the formula (6-2). That is, in the presence of a base (eg, potassium hydroxide aqueous solution) in an ether solvent (eg, THF, dioxane, etc.) or an alcohol solvent (eg, ethanol, etc.) at 0 ° C. to room temperature, A corresponding compound represented by the formula (6-3) can be produced.

  The compound represented by the formula (6-4) can be produced by reacting the formula (6-3) with the compound represented by the formula (1-5). In other words, in the presence of acetic acid, the reaction is carried out at a temperature of 80 ° C. or higher in an ether solvent (eg, dioxane, diglyme) and an alcohol solvent (eg, t-butanol, ethanol, propanol, etc.). A compound represented by the formula (6-4) can be produced.

  The compound represented by the formula (6-5) can be produced by heating and refluxing the formula (6-4) in phosphorus oxychloride.

The compound represented by the formula (6-6) can be produced by reacting the compound represented by the formula (6-5) with the compound represented by the formula (R 1 -H). This reaction can be carried out under the same conditions as in the production method of formula (1-3) or formula (1-4).

(General synthesis method 7: In the case of condensed pyridine derivatives)
Scheme 7


(In the formula, each symbol has the same meaning as the above item (1A) or (1B), R represents a phenyl group, lower (for example, C1-C6) alkyl, and X represents a leaving group (halogen, OTf, etc.). Here, “Tf” represents a trifluoromethanesulfonyl group.)
The compound represented by the formula (7-5) can be produced from the compound represented by the formula (7-1) in four steps.

As the compound represented by the formula (7-1) or the formula (R 2A ″ -X), a known compound may be used, or a compound derived from a known compound by a conventional method may be used. -5) and the compound represented by the formula (R 1 -H) are synonymous with the compounds described above.

The compound represented by the formula (7-2) can be produced by reacting the compound represented by the formula (7-1) with the compound represented by the formula (NH 2 R 1A ″ ). The compound represented by the formula (7-2) is produced by carrying out the compound represented by the formula (NH 2 R 1A ″ ) of 2 equivalents or more in a solvent such as NMP and DMF at a temperature of 150 ° C. or higher. can do. If the reaction proceeds slowly or does not proceed, the temperature can be raised to about 250 ° C. using a microwave reaction apparatus.

  The compound represented by the formula (7-3) can be produced by reacting the compound represented by the formula (7-2) with the compound represented by the formula (ClC (═O) OR) or the formula (XC (═O) X). The compound represented by the formula (ClC (═O) OR) is preferably phenyl chloroformate, and the compound represented by the formula (XC (═O) X) is preferably carbonyldiimidazole or triphosgene. This reaction is carried out in the presence of a base (eg, sodium bicarbonate water, triethylamine, etc.) in a solvent such as ethyl acetate, THF, or acetonitrile at a temperature of about room temperature to about 100 ° C. to give the corresponding formula (7-3). The compounds shown can be prepared. The base may not be used depending on the reactant used.

The compound represented by the formula (7-4) can be produced by reacting the compound represented by the formula (7-3) with the compound represented by the formula (R 2A ″ -X). That is, in the presence of sodium hydride, DMF, NMP, Alternatively, the corresponding compound represented by the formula (7-4) can be produced by carrying out at room temperature in an ether solvent (eg, dioxane, diglyme, etc.).

  The compound represented by the formula (7-5) can be produced by reacting with the compound represented by the formula (1-5). This reaction can be carried out under the same conditions as in the production method of formula (1-2).

(General Synthesis Method 8: Introduction of Substituents R 5A and R 5B in A)
Scheme 8

(In the formula, each symbol has the same meaning as the above item (1A) or (1B), and X represents a leaving group (halogen, OTf, etc.), where “Tf” represents a trifluoromethanesulfonyl group. The compound represented by 5A- B (OR) 2 means the corresponding boronic acid or boronic ester.)
Although the production method in the case where A of the compound represented by the formula (1-5) is a benzene ring is described in Scheme 8, it is not limited to the method described above.

  The compound represented by the formula (8-5) can be produced from the compound represented by the formula (8-1) in 4 steps.

As the compound represented by the formula (8-1), R 5A -B (OR) 2 (boronic acid or boronic ester) or the formula (R 5B ′ -X), a known compound may be used. A compound derived from a compound by a conventional method may be used. PG described above represents a hydroxyl-protecting group, and examples thereof include ether-based protecting groups such as a methyl group and a methoxymethyl (MOM) group, and Si-based protecting groups such as a t-butyldimethylsilyl (TBS) group. However, it is not limited to these.

  The compound represented by the formula (8-2) can be produced by deprotecting the formula (8-1) by a conventional method.

The compound represented by the formula (8-3) can be produced by reacting the compound represented by the formula (7-3) with the compound represented by the formula (R 5B ′ -X). That is, in the presence of a base (eg, potassium carbonate, sodium hydride, etc.) in DMF, NMP, or an ether solvent (eg, THF, dioxane, diglyme, etc.) at room temperature, the corresponding formula (8 -3) can be produced.

The compound represented by the formula (8-4) can be produced by a Suzuki coupling reaction between the compound represented by the formula (8-3) and the compound represented by the formula (R 5A -B (OR) 2 ). That is, in the presence of a palladium catalyst (eg, Pd (PPh 3 ) 4 , Pd 2 (dba) 3 ) and a base (eg, sodium carbonate, potassium carbonate), NMP, DMF, an ether solvent (eg, THF, dioxane) Etc.) and an alcohol solvent (eg, ethanol, propanol, etc.) at a temperature of 50 ° C. or higher, the corresponding compound represented by the formula (5-3) can be produced. This reaction is not limited to these conditions, and a known method can be applied.

  The compound represented by the formula (8-5) can be produced by a reduction reaction of a nitro group. This reaction can be carried out by a known method. For example, in the presence of palladium carbon, NMP, DMF, ethyl acetate, an ether solvent (eg, THF, dioxane, etc.), an alcohol solvent (eg, ethanol, propanol, etc.), or By carrying out under a hydrogen atmosphere in the mixed solvent, the corresponding compound represented by the formula (2-2) can be produced. This reaction is not limited to these conditions, and a known method can be applied.

(General Synthesis Method 9: Introduction of Substituent R 5A in A)
Scheme 9

(In the formula, each symbol has the same meaning as the above item (1A) or (1B), and X represents a leaving group (halogen, OTf, etc.), where “Tf” represents a trifluoromethanesulfonyl group. Can include hydrogen or any suitable substituents such as alkyl, aryl, alkenyl, acyl, amino, alkoxy, sulfamoyl, carbamoyl, etc. Also, two R together form a ring. May be.)
The compound represented by the formula (9-3) can be produced from the compound represented by the formula (9-1) in two steps.

As the compound represented by the formula (9-1) and R 5A -B (OR) 2 (boronic acid or boronic acid ester), a known compound may be used, and it is derived from a known compound by a conventional method. A compound may be used.

The compound represented by the formula (9-2) can be produced by reacting with a compound represented by the formula (R 5A -B (OR) 2 ). This reaction can be carried out under the same conditions as in the production method of formula (8-4).

  The compound represented by the formula (9-3) can be produced by a reduction reaction of a nitro group. This reaction can be carried out under the same conditions as in the production method of formula (8-5).

(General synthesis method 10: when R 2 is substituted or unsubstituted acyl, carbamoyl or carboxy)
Scheme 10

(In the formula, each symbol has the same meaning as the above item (1A) or (1B), and Alk represents lower (for example, C1-C6) alkyl. As R 2 ′ , hydrogen, alkyl, etc. are suitable as substituents. And two R 2 ′s may be combined to form a ring.)
The compound represented by formula (10-3) can be produced from the compound represented by formula (10-1) in two steps.

  The compound represented by the formula (10-2) can be produced by hydrolyzing the compound represented by the formula (10-1). The reaction solvent is ether solvent such as dioxane, THF and DME, alcohol solvent such as ethanol and methanol, solvent such as DMF, DMA, DMSO and NMP and water are mixed and water is used as the base. Lithium hydroxide or the like can be used. The reaction temperature is preferably room temperature, but may be further increased when the reaction proceeds slowly.

The compound represented by the formula (10-3) can be synthesized by condensing the compound represented by the formula (10-2) with a compound represented by the formula NH (R 2 ′ ) 2 . As the reaction solvent, DMF, NMP, DMA, dimethyl sulfoxide, dichloromethane, tetrahydrofuran, dioxane, acetonitrile and the like can be used. Examples of the condensing agent include DCC (dicyclohexylcarbodiimide), BOP (benzotriazol-1-yloxy-trisdimethylaminophosphate), PyBOP (hexafluorophosphate (benzotriazol-1-yloxy) tripyrrolidinophosphonium), PyBrop (hexafluoro). Bromotrispyrrolidinophosphonium phosphate), HATU, DPPA, WSC (1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride), DMT-MM (4- (4,6-dimethoxy-1,3, 5-triazin-2-yl) -4-methylmorpholinium chloride) and the like can be used. These reagents can be used in combination with, for example, HOSu (1-hydroxysuccinimide), HOBt (1-hydroxybenzotriazole), HOAt (1-hydroxy-7-azabenzotriazole), and the like. In some cases, it is preferably carried out in the presence of an organic amine such as triethylamine or DIEA. The reaction temperature and reaction time are not particularly limited, but the reaction is usually carried out at room temperature, and when the reaction proceeds slowly, the reaction may be promoted by heating.

(General synthesis method 11: when R 2 is substituted or unsubstituted amino)
Scheme 11

(In the formula, each symbol has the same meaning as the item (1A) or (1B), and examples of R 2 ″ include hydrogen, alkyl, and the like, which are appropriate as substituents.)
The compound represented by the formula (11-3) can be produced from the compound represented by the formula (11-1) in two steps.

  The compound represented by the formula (11-2) can be produced by reducing the compound represented by the formula (11-1). As the reaction solvent, an ether solvent such as dioxane, THF and DME, an alcohol solvent such as ethanol and methanol, a solvent such as DMF, DMA, DMSO and NMP and water are mixed and used. As the reducing agent, for example, hydrogen and palladium carbon can be used. The reaction temperature is preferably room temperature, but may be further increased when the reaction proceeds slowly.

The compound represented by the formula (11-3) is obtained by converting the compound represented by the formula (11-2) into a carboxylic acid represented by the formula R 2 ″ C (═O) OH or a corresponding acid chloride, and an acid anhydride. It can synthesize | combine by making it react. When carboxylic acid is used, it can be carried out under the same conditions as in the production method of formula (10-3). Moreover, what is necessary is just to implement according to a conventional method about reaction with an acid chloride and an acid anhydride.

  The production of the present invention can be carried out by appropriately modifying or combining the preferred embodiments described above or adding known techniques.

The compounds of the present invention can be protected using protecting groups. For example, typically, halogen (I, Br, Cl, F, etc.), lower (here, typically, C1-C6 is shown, but not limited thereto) alkoxy, lower alkylthio, lower alkylsulfonyloxy, aryl Represents sulfonyloxy and the like. ), An appropriate substituent can be protected by a method known in the art. Such protecting groups include, for example, Protective Groups in Organic Synthesis, TWGreen, John Wiley & Sons Inc. (198), such as ethoxycarbonyl, t-butoxycarbonyl, acetyl, benzyl and the like.
1 year) and the like. The method for introducing and removing the protecting group is a method commonly used in organic synthetic chemistry [for example, see Protective Groups in Organic Synthesis, TW Greene, John Wiley & Sons Inc. (1981)] or the like. It can be obtained similarly. In addition to the above production method, the functional group contained in each substituent can be converted by a known method [for example, Comprehensive Organic Transformations, RCLarock (1989), etc.]. Some can lead to further derivatives as synthetic intermediates. The intermediates and target compounds in each of the above production methods are isolated and purified by purification methods commonly used in organic synthetic chemistry, such as neutralization, filtration, extraction, washing, drying, concentration, recrystallization, and various chromatography. can do. In addition, the intermediate can be subjected to the next reaction without any particular purification.

(TTK protein kinase)
“TTK protein kinase” is an enzyme described and defined in Patent Document 3, for example, an amino acid sequence registered as Genbank NM — 003318, or a deletion or addition of one or several amino acids in the amino acid sequence. And a polypeptide containing an amino acid sequence which is inserted or substituted and has kinase activity. Here, as a preferable amino acid sequence, any of those listed in Patent Document 3 can be adopted. Here, “activity of TTK protein kinase” and “TTK activity” mean phosphorylation of threonine and / or serine and / or tyrosine. For example, in p38 MAPK (see Patent Document 3), phosphorylation of the 180th threonine and / or the 182nd tyrosine can be mentioned. TTK activity can be measured using the measurement method used in the screening method of Patent Document 3. Whether or not the polypeptide has kinase activity is determined by, for example, contacting the polypeptide, a substrate for measuring TTK activity, and a phosphate group donor, measuring TTK activity, and TTK activity of wild-type TTK protein kinase under the same conditions. Can be examined by comparing with. A known substrate for measuring TTK activity and a phosphate donor can be used. Further, the novel substrate for measuring TTK activity described in the present invention may be used. About TTK activity, what is described in a nonpatent literature 1 can be considered. And the measurement of TTK activity can mention what was described in patent document 3, for example. The TTK protein kinase may be any polypeptide having TTK protein kinase activity, that is, one or several amino acids are deleted or added in the amino acid sequence described in Patent Document 3 known as a kinase active domain. Any polypeptide that contains an amino acid sequence that may be inserted or substituted and that has kinase activity may be used. The total length of the polypeptide, addition of a modifying group, alteration of amino acid residues, and the like are appropriately selected as necessary, and are not limited to the sequences described herein. Therefore, in this specification, even when simply referred to as “TTK”, it is understood that it is used synonymously with this “TTK protein kinase” unless otherwise noted. TTK has the following alias names, which can be referred to.
TTK → TTK protein kinase (TTK PROTEIN KINASE)
hMPS1 → human monopolar spindle 1 (human MONOPOLARSPINDLE 1)
PYT → Phosphotyrosine-picked threonine kinase (PHOSPHOTYROSINE-PICKED THREONINE KINASE)
MPS1L1 → Monopolar spindle 1-like 1 (MONOPOLARSPINDLE 1-LIKE 1)
ESK → ESK, mouse ESK (= EC STY Kinase) homolog (ESK; MOUSE HOMOLOG OF ESK (= EC STY Kinase)).

  The compound obtained by the screening method of the present invention or a salt thereof can exert a therapeutic or preventive action against a disease that develops in association with an increase in TTK activity. For example, according to the screening method of the present invention, a candidate compound for a therapeutic or prophylactic agent effective for cancer, immune disease, etc. that develops due to an increase in TTK activity can be screened.

  Examples of the “cancer” include various malignant neoplasms such as solid cancer, hemangioma, hemangioendothelioma, sarcoma, Kaposi sarcoma and hematopoietic tumor, and include colon cancer and liver cancer, and further metastasis of these cancers. Is also included. The present invention has succeeded in the discovery of a novel series of compounds having specific properties that inhibit the action of TTK kinases and make them particularly useful in formulating pharmaceuticals for treating the above diseases. In particular, the compounds are particularly useful in the treatment of proliferative diseases such as cancers where TTK kinase, which develops as either a solid tumor or a hematological tumor, is known to be active, in particular colorectal cancer, It is useful in diseases such as breast cancer, lung cancer, prostate cancer, pancreatic cancer or bladder cancer and kidney cancer as well as leukemia and lymphoma.

  Examples of the “immune disease” include atopy, asthma, rheumatism, collagen disease, allergy and the like.

  Further, the compound of the present invention or a salt thereof provides a pharmaceutical composition for use in the treatment or prevention of diseases related to TTK protein kinase, for example, cancer or immune disease involving TTK protein kinase.

The pharmaceutical composition has one feature in that it contains the compound of the present invention or a salt thereof as an active ingredient. Therefore, the pharmaceutical composition exhibits an excellent effect of being able to act on the disease that develops in connection with TTK protein kinase through suppression of the activity of the enzyme. For example, the pharmaceutical composition of the present invention has an excellent effect that it can act on cancers, immune diseases, etc., particularly cancers, immune diseases, etc. that develop in relation to TTK activity, through suppression of the enzyme activity. Demonstrate. When the pharmaceutical composition is used for the treatment or prevention of cancer, conventional cancer therapy, for example, radiation therapy, chemotherapy, in particular, prior to or prior to the application of a DNA degrading agent for presensitizing tumor cells. But you can use it.

  The content of the compound or a salt thereof in the pharmaceutical composition can be appropriately adjusted depending on the disease to be treated, the age, weight, etc. of the patient, and may be any therapeutically effective amount. In the case of a compound, for example, 0.0001 to 1000 mg, preferably 0.001 to 100 mg. In the case of a polypeptide or a derivative thereof, for example, 0.0001 to 1000 mg, preferably 0.001 to 100 mg, a nucleic acid or a derivative thereof. In this case, for example, 0.00001 to 100 mg, preferably 0.0001 to 10 mg is desirable.

  The pharmaceutical composition may further contain various auxiliaries that can stably hold the compound or a salt thereof. Specifically, pharmaceutically acceptable auxiliaries, excipients, binders, and stabilizers that exhibit the property of inhibiting the active ingredient from degrading before reaching the site where the active ingredient is to be delivered. Agents, buffers, solubilizers, isotonic agents and the like.

  The dosage form of the pharmaceutical composition is appropriately selected according to the type of active ingredient; individual, organ, local site, tissue to be administered; age, weight, etc. of the individual to be administered. Examples of the administration form include subcutaneous injection, intramuscular injection, intravenous injection, and local administration.

  The dosage of the pharmaceutical composition is also appropriately selected according to the type of active ingredient; individual, organ, local site, tissue to be administered; age, weight, etc. of the individual to be administered. Although it does not specifically limit as administration, When an active ingredient is a low molecular compound or a high molecular compound, as an amount of the said active ingredient, it is 0.0001-1000 mg / kg body weight, Preferably, it is 0.001-100 mg. / Kg body weight, in the case of a polypeptide or a derivative thereof, for example, 0.0001 to 1000 mg / kg body weight, preferably 0.001 to 100 mg / kg body weight, in the case of a nucleic acid or a derivative thereof, for example, 0.00001 to 100 mg / kg Administration may be performed a plurality of times, for example, 1 to 3 times per day so as to obtain a single dose of kg body weight, preferably 0.0001 to 10 mg / kg body weight.

(Medicine)
The compound of the present invention or a pharmaceutically acceptable salt thereof can be administered alone as it is, but it is usually preferable to provide it as various pharmaceutical preparations. In addition, these pharmaceutical preparations are used for animals and humans.

  The administration route is preferably the most effective in the treatment, and can be oral or parenteral, for example, rectal, buccal, subcutaneous, intramuscular or intravenous.

  Administration forms include capsules, tablets, granules, powders, syrups, emulsions, suppositories, injections and the like. Liquid preparations such as emulsions and syrups suitable for oral administration include water, sugars such as sucrose, sorbit, fructose, glycols such as polyethylene glycol, propylene glycol, oils such as sesame oil, olive oil, soybean oil And preservatives such as p-hydroxybenzoates, and flavors such as strawberry flavor and peppermint. In addition, capsules, tablets, powders, granules, etc. are excipients such as lactose, glucose, sucrose and mannitol, disintegrants such as starch and sodium alginate, lubricants such as magnesium stearate and talc, polyvinyl It can be produced using a binder such as alcohol, hydroxypropylcellulose, gelatin, a surfactant such as fatty acid ester, and a plasticizer such as glycerin.

  Formulations suitable for parenteral administration preferably comprise a sterile aqueous formulation containing the active compound that is isotonic with the blood of the recipient. For example, in the case of an injection, a solution for injection is prepared using a carrier comprising a salt solution, a glucose solution, or a mixture of salt water and a glucose solution.

  Topical formulations are prepared by dissolving or suspending the active compound in one or more media such as mineral oil, petroleum, polyhydric alcohol and the like or other bases used in topical pharmaceutical formulations.

  Formulations for enteral administration are prepared using conventional carriers such as cacao butter, hydrogenated fat, hydrogenated fatty carboxylic acid and the like and provided as suppositories.

  In the present invention, glycols, oils, flavors, preservatives (including antioxidants), excipients, disintegrants, lubricants, binders, surfactants exemplified in oral preparations are also used in parenteral preparations. One or more auxiliary components selected from agents, plasticizers and the like can also be added.

  The effective dose and frequency of administration of the compound of the present invention or a pharmaceutically acceptable salt thereof vary depending on the administration form, patient age, body weight, nature or severity of symptoms to be treated, etc. The daily dose is 0.01 to 1000 mg / person, preferably 5 to 500 mg / person, and the administration frequency is preferably once a day or divided.

The compound of the present invention preferably has the inhibitory activity of the test substance on the basis of the fluorescence value when the TTK IC 50 in the case of screening for a compound having a TTK kinase activity inhibitory action using the p38MAPK peptide is no test substance. Is 1 μM or less, preferably 0.1 μM or less, more preferably 0.01 μM or less, or in the case of screening for cancer cell growth inhibitory compounds (A549 assay), within the range of 10 nM to 10 μM Preferably a compound having an IC 50 value of less than 10 μM, more preferably less than 1 μM.

  For further information regarding formulation, reference can be made to Chapter 25.2 of Volume 5, Pergamon Press 1990, Comprehensive Medicinal Chemistry (Corwin Hansch; Cairman of Editorial Board).

  The present invention also relates to a system, device, and kit for producing the pharmaceutical composition of the present invention. It is understood that the constituent requirements of such a system, apparatus, and kit can use those known in the art and can be appropriately designed by those skilled in the art.

  The present invention also relates to systems, devices, and kits using the compounds of the present invention, pharmaceutically acceptable salts, or solvates thereof. It is understood that the constituent requirements of such a system, apparatus, and kit can use those known in the art and can be appropriately designed by those skilled in the art.

  The compound of the present invention is a compound having utility as a medicine. Here, as usefulness as a medicine, it is a compound with high metabolic stability, low induction of drug metabolizing enzymes, small inhibition of drug metabolizing enzymes that metabolize other drugs, and high oral absorbability A point, a point with a small clearance, or a point having a sufficiently long half-life for exhibiting a medicinal effect are included.

  References such as scientific literature, patents and patent applications cited herein are hereby incorporated by reference in their entirety to the same extent as if each was specifically described.

  EXAMPLES Hereinafter, although an Example demonstrates this invention further in detail, the technical scope of this invention is not limited by this Example.

  The equipment described below was used for the equipment used and the measurement conditions.

LC / MS analysis used a Waters system (ZQ2000 mass detector; 1525 HPLC pump; 2996 photodiode array detector; 2777 autosampler). For the analysis, a reverse phase C18 column (Waters, X-Bridge C18, 4.6 × 50 mm, 5 μM) was used, and water / acetonitrile (0.1% formic acid) was used as an elution solvent. Elution conditions were 10-100% acetonitrile (3 minutes linear gradient) and 100% acetonitrile (1 minute) at a flow rate of 3 mL / min. The described LC / MS t R indicates the retention time (minute) of the target compound in LC / MS analysis, and UV at 254 nm was used for peak detection.

  Reversed phase preparative liquid chromatography was performed using a Waters system (ZQ 2000 mass detector; 2525 HPLC pump; 2996 photodiode array detector; 2777 autosampler). A reverse phase C18 column (Waters, X-Bridge, 19 × 50 mm, 5 μM) was used, and water / acetonitrile (0.1% formic acid) was used as an elution solvent. Elution conditions were 10-100% acetonitrile (5 minutes linear gradient) and 100% acetonitrile (2 minutes) at a flow rate of 25 mL / min.

  Silica gel chromatography used systems from Yamazen (YFLC-Wprep2XY), Moritex (Purif-α2), or Isco (Combi Flash Companion). The column was a Yamazen Hi-Flash column (S to 5 L), and the elution solvent was hexane / ethyl acetate or chloroform / methanol.

  1H NMR spectra were measured using Varian Gemini-300 (300 MHz) or Bruker AV-400 (400 MHz). Chemical shifts are described as δ values (ppm) using TMS (tetramethylsilane) as an internal standard. In the analysis results, s: singlet, d: doublet, t: triplet, q: quartet, m: multiplet, br: broad were used as abbreviations.

  As the microwave reactor, Biotage initiator 8 or initiator 60 was used.

(Evaluation method)
Screening of compounds with T38 kinase activity inhibitory activity using p38 MAPK peptide 1.0 μL of test substance (solvent: 10% (v / v) DMSO), 5 μL of TTK solution (composition: 4 μg / ml TTK, 25 mM Tris-HCl, pH 7.5, 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na 3 VO 4 , 5 mM MgCl 2 , 0.1% (w / v) BSA), substrate solution 5 μL (composition: 60 μM p38 MAPK peptide, 60 μM ATP, 25 mM Tris) -HCl, pH 7.5, 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM Na 3 VO 4 , 5 mM MgCl 2 , 0.1% (w / v) BSA) in polypropylene 384-well microtiter plate (Corning) Mix and place in a constant temperature humidifier. After standing overnight at a temperature of 25 ° C and a humidity of 95%, the reaction stop solution (composition: 25 mM Tris-HCl, pH 7.5, 100 mM EDTA, 0.01% (v / v) TritonX-100, 0.1% (w / v ) BSA) 50 μL was added and mixed.

Remove 1.7 μL from this, mix with 60 μL of reaction stop solution in 384-well polypropylene microtiter plate (Corning), transfer 40 μL to 384-well black NeutrAvidin plate (Pierce), seal, and seal at room temperature for 30 minutes Incubated. The plate was washed 3 times with 100 μL of TTBS (composition: 10 mM Tris, 40 mM Tris-HCl, 150 mM NaCl 2 , 0.05% (v / v) Tween 20), and then the primary antibody solution (Anti-phosphop38 antibody-28B10 (Cell Signaling) , # 9216)) was added and incubated at room temperature for 1 hour. Similarly, after washing 3 times with 100 μL of TTBS, 40 μL of secondary antibody solution (Eu-N1 labeled Anti-mouse IgG (Perkin Elmer, # AD0124)) was added and incubated at room temperature for 30 minutes. The plate was washed 5 times with 100 μL of TTBS, 40 μL of enhancement solution (Perkin Elmer) was added and incubated at room temperature for 5 minutes, and the fluorescence value at 615 nm was measured with ARVO (Perkin Elmer). Based on the fluorescence value in the absence of the test substance, the inhibitory activity of the test substance was calculated, and a compound showing a TTK kinase activity inhibitory action was obtained as a candidate compound of a TTK activity inhibitor.

Screening for cancer cell growth inhibitory compounds
Cell suspension (RERF-LC-AI, A549: 1 × 10 4 ) adjusted to an appropriate concentration by D-MEM (Nacalai Tesque) with 10% FBS (High clone) / ml, MRC5: 3 × 10 4 / ml and 1 × 10 5 / ml) were added to a 96-well plate (hereinafter, well plate) at 100 μL / well and cultured in a 37 ° C. CO 2 incubator for 1 day. 2 μL of 10 mM compound (100% DMSO solution) that showed TTK kinase activity inhibitory action in a 96-well assay block was added to 998 μL of the culture solution to prepare a 20 μM solution, and 10 concentrations were prepared in a 2-fold dilution series. Next, 100 μL / well of the above compound dilution was added to each well of the well plate in which the cells were prepared to give 200 μL / well. Thereafter, the cells were further cultured in a 37 ° C. CO 2 incubator for 3 days. 10 μL each of WST-8 kit (Kishida Chemical) solution for cell number measurement was added to each well of the well plate, and a color reaction was performed for 1 to 4 hours in a CO 2 incubator. A compound that shows growth inhibitory activity in cancer cells after measuring the absorbance at 450 nm (reference wavelength 620 nm) with a microplate reader and calculating the inhibitory activity of the test substance based on the absorbance value without the test substance Selected.

Example 1
Example 1-1
Methyl-2- (cyclohexylamino) -6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) nicotinate


Step 1: Methyl-6-chloro-2- (cyclohexylamino) nicotinate Methyl-6-chloro-2- (cyclohexylamino) nicotinate (5.65 g, 27.4 mmol) in NMP (20 mL) was added to cyclohexylamine (5.71 g , 6.59 mL, 57.6 mmol) and stirred at room temperature for 5 hours. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered, concentrated under reduced pressure, and the residue was solidified with dichloromethane / ether to give the title compound (4.03 g, 15.0 mmol, 55%) as a colorless solid.
1H-NMR (400 MHz, DMSO-d6) δ 1.27-1.38 (m, 5H), 1.53 (brs, 1H), 1.64 (brs, 2H), 1.90 (brs, 2H), 3.80 (s, 3H), 3.91 (s, 1H), 6.61 (d, J = 7.8 Hz, 1H), 8.04 (d, J = 7.8 Hz, 1H), 8.08 (d, J = 8.1 Hz, 1H).
MS (ESI) m / z = 269 (M + H) + .
LC / MS t R = 2.85 min.

Step 2: Methyl 2- (cyclohexylamino) -6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) nicotinate Methyl 6-chloro-2- (cyclohexylamino) nicotinate ( 213 mg, 0.793 mmol), 3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) aniline (177 mg, 0.872 mmol), Xantphos (68.8 mg, 0.119 mmol), and cesium carbonate (387 mg) , 1.19 mmol) in dioxane (2.0 mL) was added Pd (OAc) 2 (17.8 mg, 0.079 mmol) and stirred for 8 hours under reflux. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The obtained residue was purified by reverse phase HPLC (acetonitrile / water / 0.3% formic acid: 10-100% acetonitrile) to give the title compound (344 mg, 0.789 mmol, 100%) as a brown solid.
1H-NMR (400 MHz, DMSO-d6) δ 1.23-1.42 (m, 5H), 1.54-1.60 (m, 1H), 1.68 (br s, 2H), 1.96 (br s, 2H), 3.16 (d, J = 5.1 Hz, 1H), 3.72 (s, 3H), 3.85 (s, 3H), 3.87 (s, 3H), 4.03-4.10 (m, 1H), 6.02 (d, J = 8.8 Hz, 1H), 7.27 (s, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.79 (s, 1H), 7.82 (s, 1H), 8.02 (s, 1H ), 8.21 (d, J = 7.1 Hz, 1H), 9.39 (s, 1H).
MS (ESI) m / z = 436 (M + H) + .
LC / MS t R = 2.48 min.

Example 1-2
2- (Cyclohexylamino) -6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) nicotinic acid


Add 2N to a solution of methyl 2- (cyclohexylamino) -6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) nicotinate (144 mg, 0.332 mmol) in DMSO (3.0 mL). A sodium hydroxide aqueous solution (633 μL) was added, and the mixture was stirred at 80 ° C. for 3 hours. A 2N aqueous hydrochloric acid solution was added, and then ethyl acetate was added for separation. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered, and the reaction solution was concentrated to give the title compound (344 mg, 0.789 mmol, 100%) as a brown solid.
1H-NMR (400 MHz, DMSO-d6) δ 1.28-1.41 (m, 5H), 1.58 (br s, 1H), 1.68 (br s, 2H), 1.97 (br s, 2H), 3.84 (s, 3H ), 3.87 (s, 3H), 4.02 (s, 1H), 6.00 (d, J = 8.3 Hz, 1H), 7.28 (s, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.54 (d , J = 7.6 Hz, 1H), 7.79 (d, J = 8.8 Hz, 1H), 7.82 (s, 1H), 8.01 (s, 1H), 8.35 (d, J = 7.1 Hz, 1H), 9.31 (s , 1H), 12.02 (s, 1H).
MS (ESI) m / z = 422 (M + H) + .
LC / MS t R = 1.92 min.

Example 1-3
2- (Cyclohexylamino) -N-cyclopropyl-6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) nicotinamide

2- (cyclohexylamino) -6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) nicotinic acid (54.4 mg, 0.129 mmol), DIEA (41.7 mg, 56 μL, 0.323 mmol) and cyclopropylamine (14.7 mg, 0.258 mmol) in DMF (0.5 mL) were added HATU (98 mg, 0.258 mol) and stirred for 5 hours. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with saturated aqueous sodium bicarbonate, 0.1 mol / L hydrochloric acid, and saturated brine, and magnesium sulfate. Dried. The organic phase was filtered and concentrated under reduced pressure. The resulting residue was purified by reverse phase HPLC (acetonitrile / water / 0.3% formic acid: 10-100% acetonitrile) to give the title compound (19.9 mg, 0.043 mmol, 34%) Was obtained as a white solid.
1H-NMR (400 MHz, DMSO-d6) δ 0.50 (br s, 2H), 0.63 (br s, 2H), 1.23-1.41 (m, 6H), 1.57 (br s, 1H), 1.68 (br s, 2H), 1.94 (br s, 2H), 2.72 (br s, 1H), 3.84 (s, 3H), 3.85 (s, 3H), 3.99 (br s, 1H), 7.26 (s, 1H), 7.41 ( d, J = 8.6 Hz, 1H), 7.49 (d, J = 7.3 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.80 (s, 1H), 7.92 (s, 1H), 7.99 ( s, 1H), 9.05 (d, J = 7.6 Hz, 1H), 9.11 (s, 1H).
MS (ESI) m / z = 461 (M + H) + .
LC / MS t R = 2.02 min.

Example 1-8
N- (Cyanomethyl) -6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) -2- (tetrahydro-2H-pyran-4-ylamino) nicotinamide

The title compound was synthesized according to the method of Example 1-3.
1H-NMR (400 MHz, DMSO-d6) δ 1.47 (m, 2H), 2.00 (m, 2H), 3.49 (t, 2H, J = 11.1 Hz), 3.86 (s, 3H), 3.87 (m, 2H ), 3.88 (s, 3H), 4.18 (s, 1H), 4.22 (d, 2H, J = 4.0 Hz), 6.02 (d, 1H, J = 8.1 Hz), 7.18 (s, 1H), 7.48 (d , 1H, J = 8.6 Hz), 7.57 (d, 1H, J = 8.6 Hz), 7.76 (d, 1H, J = 8.1 Hz), 7.84 (s, 1H), 8.03 (s, 1H), 8.64 (s , 1H), 8.90 (d, 1H, J = 6.6 Hz), 9.29 (s, 1H).
MS (ESI) m / z = 462 (M + H) + .
LC / MS t R = 1.54 min.

Example 1-9
N- (2- (cyclohexyloxy) -6- (4- (1-methyl-1H-pyrazol-4-yl) phenylamino) pyridin-3-yl) acetamide

Step 1: 6- (Cyclohexyloxy) -N- (4- (1-methyl-1H-pyrazol-4-yl) phenyl) -5-nitropyridin-2-amine cyclohexanol (778 mg, 7.77 mmol), and 2,6-Dichloro-3-nitropyridine (1.0 g, 5.18 mmol) was added to an NMP solution (7 mL) of 60% sodium hydride (249 mg, 6.22 mol), and the mixture was stirred at room temperature for 1 hour. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The resulting residue was purified by medium pressure silica gel chromatography (hexane: ethyl acetate = 95: 5) to give 6-chloro-2- (cyclohexyloxy) -3-nitropyridine. (956 mg, 1.86 mmol, 72%) was obtained as a colorless oil.

6-chloro-2- (cyclohexyloxy) -3-nitropyridine (444 mg, 0.865 mmol), 4- (1-methyl-1H-pyrazol-4-yl) aniline (360 mg, 2.08 mmol), Xantphos (200 Pd (OAc) 2 (38.8 mg, 0.173 mmol) was added to a dioxane (4.0 mL) solution of mg, 0.346 mmol) and potassium carbonate (359 mg, 2.59 mmol), and the mixture was stirred for 3 hours under reflux. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The obtained residue was purified by medium pressure silica gel chromatography (hexane / ethyl acetate: 30% ethyl acetate) to give the title compound (206 mg, 0.523 mmol, 30%) as a red-brown solid.
1H-NMR (400 MHz, DMSO-d6) δ 1.38-1.49 (m, 3H), 1.62 (br s, 4H), 1.79 (br s, 2H), 1.99 (br s, 3H), 3.86 (s, 3H ), 5.17 (br s, 1H), 6.45 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 7.6 Hz, 2H), 7.66 (d, J = 7.6 Hz, 2H), 7.83 (s, 1H), 8.11 (s, 1H), 8.25 (d, J = 9.1 Hz, 1H).

Step 2: 6- (Cyclohexyl) -N 2- (4- (1-Methyl-1H-pyrazol-4-yl) phenyl) pyridine-2,5-diamine
6- (cyclohexyloxy) -N- (4- (1-methyl-1H-pyrazol-4-yl) phenyl) -5-nitropyridin-2-amine (25 mg, 0.073 mmol) in THF: methanol = 1: To 1 (8 mL) solution was added 10% palladium on carbon (26 mg), and the mixture was stirred at room temperature for 8 hours in a hydrogen atmosphere. The reaction solution was filtered through Celite, and the obtained residue was solidified and washed with hexane to give the title compound (111 mg, 0.305 mmol, 88%) as a black solid.
MS (ESI) m / z = 364 (M + H) + .
LC / MS t R = 1.35 min.

Step 3: N- (2- (cyclohexyloxy) -6- (4- (1-methyl-1H-pyrazol-4-yl) phenylamino) pyridin-3-yl) acetamide
6- (cyclohexyl) -N 2- (4- (1-methyl-1H-pyrazol-4-yl) phenyl) pyridine-2,5-diamine (35 mg, 0.096 mmol) and triethylamine (48.7 mg, 67 μL , 0.481 mmol) in THF (2.0 mL) was added acetic anhydride (19.7 mg, 18 μL, 0.193 mol) and stirred at room temperature for 1 hour. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with saturated aqueous sodium hydrogen carbonate and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The obtained residue was purified by medium pressure silica gel chromatography (hexane / ethyl acetate: 80% ethyl acetate) to give the title compound (8.3 mg, 0.020 mmol, 23%) as beige. Obtained as a colored solid.
1H-NMR (400 MHz, DMSO-d6) δ 1.30 (m, 1H), 1.41-1.62 (m, 5H), 1.80 (m, 2H), 2.03 (s, 3H), 2.03 (m, 2H), 3.85 (s, 3H), 4.96 (m, 1H), 6.33 (d, 1H, J = 8.1 Hz), 7.42 (d, 2H, J = 7.6 Hz), 7.60 (d, 2H, J = 7.6 Hz), 7.76 (s, 1H), 7.80 (d, 1H, J = 8.1 Hz), 8.02 (s, 1H), 8.86 (s, 1H), 8.95 (s, 1H).
MS (ESI) m / z = 406 (M + H) + .
LC / MS t R = 1.87 min.

Example 1-10
2- (Cyclohexyloxy) -N-cyclopropyl-6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) nicotinamide

Step 1: 2,6-Dichloro-N-cyclopropylnicotinamide Implemented in the same manner as in Example 1-3 to obtain the title compound (265 mg, 1.15 mmol, 73%) as a white solid.
1H-NMR (400 MHz, DMSO-d6) δ 0.51 (s, 2H), 0.70 (d, J = 6.3 Hz, 2H), 2.80 (s, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 8.65 (s, 1H).

Step 2: 6-chloro-2- (cyclohexyloxy) -N-cyclopropylnicotinamide 2 in NMP solution (2 mL) of cyclohexanol (195 mg, 1.95 mmol) and sodium hydride (51.9 mg, 1.30 mmol) , 6-Dichloro-N-cyclopropylnicotinamide (150 mg, 0.649 mmol) 60% was added and stirred at room temperature for 3 hours. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The obtained residue was purified by medium pressure silica gel chromatography (hexane / ethyl acetate: 40-50% ethyl acetate gradient) to give 6-chloro-2- (cyclohexyloxy)- N-cyclopropylnicotinamide (184 mg, 0.623 mmol, 96%) was obtained as a colorless oil.
MS (ESI) m / z = 295 (M + H) + .
LC / MS t R = 2.39 min.

Step 3: 2- (cyclohexyloxy) -N-cyclopropyl-6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) nicotinamide Example 1-1, Step 2 The title compound (51.1 mg, 0.111 mmol, 60%) was obtained as a beige amorphous substance.
1H-NMR (400 MHz, DMSO-d6) δ 0.48 (m, 2H), 0.75 (m, 2H), 1.47 (br, 4H), 1.65 (m, 4H), 1.98 (m, 2H), 2.85 (m , 1H), 3.86 (s, 3H), 3.88 (s, 3H), 5.26 (m, 1H), 6.48 (d, 1H, J = 8.6 Hz), 7.22 (s, 1H), 7.38 (d, 2H, J = 8.6 Hz), 7.49 (d, 1H, J = 8.6 Hz), 7.83 (s, 1H), 7.87 (m, 1H), 8.03 (s, 1H), 8.06 (d, 1H, J = 8.6 Hz) , 9.51 (s, 1H).
MS (ESI) m / z = 462 (M + H) + .
LC / MS t R = 2.13 min.

Example 1-11
6- (4-Carbamoylphenylamino) -2- (cyclohexyloxy) -N-cyclopropylnicotinamide


The title compound was synthesized according to the method of Example 1-10.
MS (ESI) m / z = 395 (M + H) + .
LC / MS t R = 1.68 min.

Example 1-12
2- (Cyclohexylamino) -6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) -4-methylnicotinamide


The title compound was synthesized according to the method of Example 1-1.
MS (ESI) m / z = 435 (M + H) + .
LC / MS t R = 1.86 min.

Example 1-13
2- (Cyclohexyloxy) -6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) -4-methylnicotinamide


The title compound was synthesized according to the method of Example 1-10.
1H-NMR (400 MHz, DMSO-d6) δ 1.36 (m, 3H), 1.54 (m, 3H), 1.74 (m, 2H), 1.91 (m, 2H), 2.20 (s, 3H), 3.85 (s , 3H), 3.86 (s, 3H), 5.06 (m, 1H), 6.22 (s, 1H), 7.27 (s, 2H), 7.30 (d, 1H, J = 8.6 Hz), 7.37 (s, 1H) , 7.44 (d, 1H, J = 8.6 Hz), 7.81 (s, 1H), 8.00 (s, 1H), 9.06 (s, 1H).
MS (ESI) m / z = 435 (M + H) + .
LC / MS t R = 1.86 min.

Example 1-14
1- (2- (cyclohexylamino) -6- (4- (1-methyl-1H-pyrazol-4-yl) phenylamino) pyridin-3-yl) ethanone


The title compound was synthesized according to the method of Example 1-1.
MS (ESI) m / z = 420 (M + H) + .
LC / MS t R = 2.24 min.

Example 1-15
2- (5- (6- (cyclohexylamino) -5- (1-methyl-1H-pyrazol-4-yl) pyridin-2-ylamino) -2- (1-methyl-1H-pyrazol-4-yl) Phenoxy) acetonitrile

Step 1-1: 2-Bromo-5-nitrophenol
To a solution of 1-bromo-2-methoxy-4-nitrobenzene (5.0 g, 21.6 mmol) in dichloromethane (50 mL) was added BBr 3 (1 M DCM solution, 32.3 mL) at 0 ° C. and stirred overnight. Water and ethyl acetate were added to the reaction solution and separated. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The resulting residue was purified by medium pressure silica gel chromatography (hexane / ethyl acetate: 10% ethyl acetate) to give the title compound (3.16 g, 14.5 mmol, 67%). Obtained as a white solid.
1H-NMR (300 MHz, CDCl 3 ) δ 7.57 (d, J = 8.3 Hz, 1H), 7.70 (s, 1H), 7.77 (d, J = 8.3 Hz, 1H), 11.35 (s, 1H).

Step 1-2: 2- (2-Bromo-5-nitrophenoxy) acetonitrile
Bromoacetonitrile (3.72 g, 2.16 mL, 31.0 mmol) was added to a solution of 2-bromo-5-nitrophenol (5.64 g, 25.9 mmol) and potassium carbonate (10.7 g, 78.0 mmol) in acetonitrile (100 mL). Thereafter, the mixture was stirred at room temperature overnight. Water and ethyl acetate were added to the reaction solution and separated. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and then concentrated under reduced pressure. The obtained residue was purified by medium pressure silica gel chromatography (hexane / ethyl acetate: 10-50% ethyl acetate gradient) to give the title compound (6.69 g, 26.0 mmol, 100 %) As an orange solid.
1H-NMR (300 MHz, DMSO-d6) δ 5.49 (s, 2H), 7.89 (dd, J = 8.6, 2.4 Hz, 1H), 7.99 (d, J = 8.6 Hz, 1H), 8.07 (d, J = 2.4 Hz, 1H).

Step 1-3: 2- (2- (1-Methyl-1H-pyrazol-4-yl) -5-nitrophenoxy) acetonitrile
1-methyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-pyrazole (6.50 g, 31.2 mmol), 2- (2-bromo-5 -Nitrophenoxy) acetonitrile (6.69 g, 26.0 mmol) and PdCl 2 (dppf) · CH 2 Cl 2 (2.13 g, 2.61 mmol) in THF (80 mL) were added with 2M sodium carbonate aqueous solution (26 mL). The mixture was stirred for 8 hours under heating to reflux. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered, concentrated under reduced pressure, and solidified with ethyl acetate to give the title compound (4.39 g, 17.0 mmol, 65%) as a yellow solid.
1H-NMR (300 MHz, DMSO-d6) δ 3.91 (s, 3H), 5.49 (s, 2H), 7.96-7.97 (m, 2H), 8.04 (d, J = 1.3 Hz, 1H), 8.09 (s , 1H), 8.36 (s, 1H).

Step 1-4: 2- (5-Amino-2- (1-methyl-1H-pyrazol-4-yl) phenoxy) acetonitrile Performed in the same manner as in Example 1-9 and Step 2, and the residue was medium pressure The title compound (1.27 g, 5.54 mmol, 33%) was obtained by purification by silica gel chromatography (chloroform / ethyl acetate; 20-100% ethyl acetate gradient).
1H-NMR (300 MHz, DMSO-d6) δ 3.82 (s, 3H), 5.08 (s, 2H), 5.24 (s, 2H), 6.29 (d, J = 8.2 Hz, 1H), 6.34 (d, J = 2.0 Hz, 1H), 7.23 (d, J = 8.2 Hz, 1H), 7.66 (s, 1H), 7.84 (s, 1H).

Step 2-1: 6-Chloro-N-cyclohexyl-3-iodopyridin-2-amine
Cyclohexylamine (5.45 g, 6.29 mL, 55.0 mmol) was added to a solution of 2,6-dichloro-3-iodopyridine (6.85 g, 25.0 mmol) in NMP (100 mL), and the mixture was stirred at 100 ° C. for 8 hours. . Water and ethyl acetate were added to the reaction solution and separated. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The resulting residue was purified by medium pressure silica gel chromatography (hexane / ethyl acetate: 10-90% ethyl acetate gradient) to give the title compound (4.65 g, 13.8 mmol, 55 %).
1H-NMR (300 MHz, DMSO-d6) δ 1.20-1.36 (m, 6H), 1.57-1.61 (m, 1H), 1.68-1.72 (m, 2H), 1.83-1.86 (m, 2H), 3.75- 3.76 (m, 1H), 5.56 (d, J = 7.8 Hz, 1H), 6.38-6.41 (m, 1H), 7.88 (d, J = 7.8 Hz, 1H).

Step 2-2: 6-chloro-N-cyclohexyl-3- (1-methyl-1H-pyrazol-4-yl) pyridin-2-amine Performed in the same manner as in Step 1-3, and the title compound (3.14 g , 10.8 mmol, 78%) was obtained as a red oil.
1H-NMR (300 MHz, DMSO-d6) δ 1.14-1.35 (m, 5H), 1.60-1.67 (m, 3H), 1.86-1.89 (m, 2H), 3.88 (s, 3H), 5.46 (d, J = 7.9 Hz, 1H), 6.58 (d, J = 7.7 Hz, 1H), 7.36 (d, J = 7.7 Hz, 1H), 7.64 (s, 1H), 7.95 (s, 1H).

Step 2-3: 2- (5- (6- (cyclohexylamino) -5- (1-methyl-1H-pyrazol-4-yl) pyridin-2-ylamino) -2- (1-methyl-1H-pyrazole -4-yl) phenoxy) acetonitrile The title compound (71.9 mg, 0.149 mmol, 43%) was obtained in the same manner as in Example 1-1, Step 2.
1H-NMR (300 MHz, DMSO-d6) δ 1.28-1.35 (m, 5H), 1.68-1.71 (m, 3H), 1.99-2.02 (m, 2H), 3.86-3.87 (m, 7H), 4.99 ( d, J = 7.6 Hz, 1H), 5.12 (s, 2H), 6.09 (d, J = 8.1 Hz, 1H), 7.22-7.23 (m, 2H), 7.44 (d, J = 8.6 Hz, 1H), 7.56 (s, 1H), 7.72 (dd, J = 8.6, 1.8 Hz, 1H), 7.79 (s, 1H), 7.83 (s, 1H), 8.00 (s, 1H), 8.89 (s, 1H).
MS (ESI) m / z = 483 (M + H) + .
LC / MS t R = 1.78 min.

Example 1-16
2- (5- (6- (cyclohexylamino) -5- (oxazol-5-yl) pyridin-2-ylamino) -2- (1-methyl-1H-pyrazol-4-yl) phenoxy) acetonitrile

Step 1: 5- (2,6-dichloropyridin-3-yl) oxazole
To a solution of 2,6-dichloronicotinaldehyde (4.90 g, 27.8 mmol) and TosMIC (6.52 g, 33.4 mmol) in methanol (60 mL) was added potassium carbonate (5.00 g, 36.2 mmol), and then heated under reflux. For 2 hours. Water and ethyl acetate were added to the reaction solution and separated. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The obtained residue was purified by medium pressure silica gel chromatography (hexane / ethyl acetate: 30% ethyl acetate) to give the title compound (3.74 g, 17.4 mmol, 63%). Obtained.
1H-NMR (300 MHz, DMSO-d6) δ 7.73 (d, J = 8.2 Hz, 1H), 7.94 (s, 1H), 8.29 (d, J = 8.2 Hz, 1H), 8.67 (s, 1H).

Step 2: 6-Chloro-N-cyclohexyl-3- (oxazol-5-yl) pyridin-2-amine
After adding cyclohexylamine (436 mg, 0.503 mL, 4.40 mmol) to NMP (2.0 mL) solution of 5- (2,6-dichloropyridin-3-yl) oxazole (430 mg, 2.0 mmol), microwave The mixture was stirred at 150 ° C. for 10 hours under irradiation. Water and ethyl acetate were added to the reaction solution and separated. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The resulting residue was purified by medium pressure silica gel chromatography (hexane / ethyl acetate: 10% ethyl acetate) to give the title compound (126 mg, 0.454 mmol, 18%). Obtained.
1H-NMR (300 MHz, DMSO-d6) δ 1.15-1.41 (m, 6H), 1.58-1.72 (m, 3H), 1.89-1.92 (m, 2H), 3.87-3.88 (m, 1H), 6.03 ( d, J = 7.7 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 7.54 (s, 1H), 7.70 (d, J = 7.9 Hz, 1H), 8.47 (s, 1H).

Step 3: 2- (5- (6- (Cyclohexylamino) -5- (oxazol-5-yl) pyridin-2-ylamino) -2- (1-methyl-1H-pyrazol-4-yl) phenoxy) acetonitrile Example 1-1 was carried out in the same manner as in step 2, and the title compound (95 mg, 0.202 mmol, 45%) was obtained.
1H-NMR (300 MHz, DMSO-d6) δ 1.34-1.42 (m, 5H), 1.66-1.70 (m, 3H), 2.00-2.03 (m, 2H), 3.86 (s, 3H), 3.94-3.97 ( m, 1H), 5.14 (s, 2H), 5.58 (d, J = 7.6 Hz, 1H), 6.16 (d, J = 8.2 Hz, 1H), 7.22 (d, J = 1.6 Hz, 1H), 7.30 ( s, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.55 (d, J = 8.2 Hz, 1H), 7.77 (dd, J = 8.5, 1.6 Hz, 1H), 7.81 (s, 1H), 8.02 (s, 1H), 8.35 (s, 1H), 9.18 (s, 1H).
MS (ESI) m / z = 470 (M + H) + .
LC / MS t R = 2.00 min.




Examples 1-24
6- (3- (Cyanomethoxy) -4- (1-methyl-1H-pyrazol-4-yl) phenylamino) -2- (cyclohexylamino) nicotinonitrile

Step 1: 6- (4-Bromo-3-methoxyphenylamino) -2-chloronicotinonitrile
To a solution of 2,6-dichloronicotinonitrile (9.15 g, 52.9 mmol) and DIEA (10.3 g, 13.9 mL, 79 mmol) in NMP (130 mL) was added 4-bromo-3-methoxyaniline (12.8 g, 63.5 mmol) and then stirred at 100 ° C. for 10 hours. Water and ethyl acetate were added to the reaction solution and separated. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and then concentrated under reduced pressure. A methanol / chloroform / hexane solution (40 mL / 60 mL / 480 mL) was added to the resulting residue to solidify, and the title compound (11.5 g, 34.1 mmol) was collected by filtration. , 64%) as a white solid.
1H-NMR (300 MHz, DMSO-d6) δ 3.85 (s, 3H), 6.87 (d, J = 8.7 Hz, 1H), 7.14 (dd, J = 8.7, 2.4 Hz, 1H), 7.51-7.52 (m , 2H), 8.00 (d, J = 8.7 Hz, 1H), 10.24 (s, 1H).

Step 2: 6- (4-Bromo-3-methoxyphenylamino) -2- (cyclohexylamino) nicotinonitrile
After adding cyclohexylamine (15.3 mL, 15.3 mmol) to a solution of 6- (4-bromo-3-methoxyphenylamino) -2-chloronicotinonitrile (9.03 g, 26.7 mmol) in NMP (90 mL), Stir at 150 ° C. for 5 hours. The reaction solution was returned to room temperature, poured into ice water, and the obtained solid was collected by filtration to give the title compound (9.74 g, 24.3 mmol, 91%) as a yellow solid.
1H-NMR (300 MHz, DMSO-d6) δ 1.21-1.33 (br m, 5H), 1.63-1.73 (m, 3H), 1.87-1.90 (m, 2H), 3.84 (s, 4H), 6.04 (d , J = 8.4 Hz, 1H), 6.40 (d, J = 7.8 Hz, 1H), 7.18 (d, J = 2.3 Hz, 1H), 7.40 (d, J = 8.7 Hz, 1H), 7.48-7.55 (m , 2H), 9.50 (s, 1H).

Step 3: 6- (4-Bromo-3-hydroxyphenylamino) -2- (cyclohexylamino) nicotinonitrile Example 1-15 was carried out in the same manner as in Step 1-1, and the title compound (9.93 g, 25.6 mmol, 100%) as a brown solid.
1H-NMR (300 MHz, DMSO-d6) δ 1.14-1.40 (m, 7H), 1.64-1.69 (m, 3H), 1.90 (br s, 2H), 3.84 (s, 1H), 6.02 (d, J = 8.4 Hz, 1H), 6.35 (d, J = 7.5 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 7.29 (d, J = 8.8 Hz, 1H), 7.40 (dd, J = 8.8 , 2.4 Hz, 1H), 7.50 (d, J = 8.4 Hz, 1H), 9.36 (s, 1H), 10.02 (s, 1H).

Step 4: 6- (4-Bromo-3- (cyanomethoxy) phenylamino) -2- (cyclohexylamino) nicotinonitrile Example 1-15 was carried out in the same manner as in Step 1-2, and the title compound (7.10 g, 16.7 mmol, 70%) was obtained as a pale green solid.
1H-NMR (300 MHz, DMSO-d6) δ 1.13-1.43 (m, 6H), 1.64-1.74 (m, 3H), 1.91 (br s, 2H), 3.85 (br s, 1H), 5.20 (s, 2H), 6.07 (d, J = 8.6 Hz, 1H), 6.44 (d, J = 7.7 Hz, 1H), 7.31 (d, J = 2.2 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H) , 7.56 (d, J = 8.6 Hz, 1H), 7.68 (dd, J = 8.8, 2.3 Hz, 1H), 9.63 (s, 1H).

Process 5:
Example 1-15 The method was carried out in the same manner as in Step 1-3 to obtain the title compound (1.89 g, 4.42 mmol, 45%) as a yellow solid.
1H-NMR (300 MHz, DMSO-d6) δ 1.20 (m, 1H), 1.37 (m, 4H), 1.66 (m, 1H), 1.76 (m, 2H), 1.93 (m, 2H), 3.87 (s , 3H), 3.87 (m, 1H), 5.16 (s, 2H), 6.08 (d, 1H, J = 8.6 Hz), 6.37 (d, 1H, J = 7.1 Hz), 7.24 (s, 1H), 7.52 (d, 1H, J = 8.6 Hz), 7.54 (d, 1H, J = 8.6 Hz), 7.72 (d, 1H, J = 8.6 Hz), 7.84 (s, 1H), 8.06 (s, 1H), 9.54 (s, 1H).
MS (ESI) m / z = 428 (M + H) + .
LC / MS t R = 2.11 min.

















Example 1-79
(E) -3- (4- (5-Cyano-6- (cyclohexylamino) pyridin-2-ylamino) -2- (cyanomethoxy) phenyl) acrylamide

Acrylamide (12.1 mg, 0.171 mmol), 6- (4-Bromo-3- (cyanomethoxy) phenylamino) -2- (cyclohexylamino) nicotinonitrile (48.7 mg, 0.114 mmol), and Pd [P (t- Triethylamine (23.1 mg, 0.228 mmol) was added to a NMP (1.2 mL) solution of Bu) 3 ] 2 (5.84 mg, 0.011 mmol), and the mixture was stirred for 8 hours under microwave irradiation. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The resulting residue was purified by medium pressure silica gel chromatography (chloroform / methanol: 5% methanol) to give the title compound (26.6 mg, 0.064 mmol, 56%) as a yellow solid. Got as.
1H-NMR (300 MHz, DMSO-d6) δ 1.14-1.45 (5H, m), 1.63-1.78 (3H, m), 1.92-1.95 (2H, m), 3.88 (1H, br s), 5.19 (2H , s), 6.11 (1H, d, J = 8.5 Hz), 6.49 (1H, d, J = 9.0 Hz), 6.54 (1H, d, J = 15.0 Hz), 7.02 (1H, br s), 7.15 ( 1H, s), 7.48-7.62 (4H, m), 7.86 (1H, d, J = 8.8 Hz), 9.73 (1H, s).
MS (ESI) m / z = 417 (M + H) + .
LC / MS t R = 1.78 min.

Example 1-80
N 2 -cyclohexyl-N 6- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenyl) -3-methylpyridine-2,6-diamine

The title compound was synthesized according to the method of Example 1-24.
MS (ESI) m / z = 392 (M + H) + .
LC / MS t R = 1.58 min.

Example 1-81
(E) -3- (6- (3- (Cyanomethoxy) -4- (1-methyl-1H-pyrazol-4-yl) phenylamino) -2- (cyclohexylamino) pyridin-3-yl) -N -Cyclopropylacrylamide

Step 1: (E) -methyl 3- (6-chloro-2- (cyclohexylamino) pyridin-3-yl) acrylate acrylamide (12.1 mg, 0.171 mmol), 6- (4-bromo-3- (cyanomethoxy) Phenylamino) -2- (cyclohexylamino) nicotinonitrile (48.7 mg, 0.114 mmol) and Pd [P (t-Bu) 3 ] 2 (5.84 mg, 0.011 mmol) in NMP (1.2 mL) solution in triethylamine (1.2 mL) 23.1 mg, 0.228 mmol) was added and stirred for 8 hours under microwave irradiation. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The resulting residue was purified by medium pressure silica gel chromatography (chloroform / methanol: 5% methanol) to give the title compound (26.6 mg, 0.064 mmol, 56%) as a yellow solid. Got as.
1H-NMR (300 MHz, DMSO-d6) δ 1.13-1.31 (m, 5H), 1.65-1.81 (m, 5H), 3.71 (s, 3H), 3.84-3.85 (m, 1H), 6.46-6.54 ( m, 2H), 6.95 (d, J = 7.7 Hz, 1H), 7.80-7.84 (m, 2H).

Step 2: (E) -3- (6-Chloro-2- (cyclohexylamino) pyridin-3-yl) acrylic acid
(E) -Methyl 3- (6-chloro-2- (cyclohexylamino) pyridin-3-yl) acrylate (767 mg, 2.60 mmol) in methanol / THF solution (4.0 mL / 4.0 mL) in 4 mol / L water An aqueous sodium oxide solution (1.95 mL) was added, and the mixture was stirred at room temperature for 4 hours. After acidifying with 2 mol / L hydrochloric acid aqueous solution, ethyl acetate was added and separated. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered, and then the reaction solution was concentrated to obtain the title compound (831 mg).
1H-NMR (300 MHz, DMSO-d6) δ 1.11-1.27 (br m, 5H), 1.56-1.83 (m, 5H), 3.79 (br s, 1H), 6.33 (d, J = 15.6 Hz, 1H) , 6.42 (br s, 1H), 6.50 (d, J = 7.9 Hz, 1H), 7.52 (d, J = 15.6 Hz, 1H), 7.64 (d, J = 7.9 Hz, 1H).

Step 3: (E) -3- (6-Chloro-2- (cyclohexylamino) pyridin-3-yl) -N-cyclopropylacrylamide Performed in the same manner as in Example 1-3, and the title compound (428 mg , 1.34 mmol, 52%).
1H-NMR (300 MHz, DMSO-d6) δ 0.43-0.46 (m, 2H), 0.67-0.69 (m, 2H), 1.12-1.35 (m, 5H), 1.65-1.81 (m, 5H), 2.72- 2.76 (m, 1H), 3.82-3.83 (m, 1H), 6.34 (d, J = 15.4 Hz, 1H), 6.54 (d, J = 7.9 Hz, 1H), 6.69 (d, J = 7.7 Hz, 1H ), 7.50-7.54 (m, 2H), 8.13 (d, J = 4.4 Hz, 1H).

Step 4: (E) -3- (6- (3- (cyanomethoxy) -4- (1-methyl-1H-pyrazol-4-yl) phenylamino) -2- (cyclohexylamino) pyridin-3-yl ) -N-cyclopropylacrylamide The title compound (11.9 mg, 0.023 mmol, 7%) was obtained in the same manner as in Example 1-1 / Step 2.
1H-NMR (300 MH, DMSO-d6) δ 0.43-0.44 (m, 2H), 0.65-0.67 (m, 2H), 1.20-1.35 (m, 5H), 1.74-1.77 (m, 3H), 1.97- 2.00 (m, 2H), 2.72-2.74 (m, 1H), 3.84-3.88 (m, 4H), 5.12 (s, 2H), 6.07-6.11 (m, 2H), 6.21 (d, J = 7.4 Hz, 1H), 7.20 (d, J = 1.8 Hz, 1H), 7.45 (dd, J = 8.5, 2.8 Hz, 2H), 7.52 (d, J = 15.4 Hz, 1H), 7.76-7.80 (m, 2H), 7.89 (d, J = 4.2 Hz, 1H), 8.02 (s, 1H), 9.15 (s, 1H).
MS (ESI) m / z = 512 (M + H) + .
LC / MS t R = 1.82 min.

Example 1-82
4- (Cyclohexylamino) -2- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) pyrimidine-5-carbonitrile

Step 1: 4-hydroxy-2- (methylthio) pyrimidine-5-carbonitrile To a solution of potassium hydroxide (2.33 g, 41.5 mmol) in methanol (15 mL), S-methylisothiourea sulfate (6.80 g, 24.4 mmol) ) Was added at 0 ° C., followed by stirring at room temperature for 1 hour. The reaction solution was filtered to remove insoluble matters. (E) -ethyl 2-cyano-3-ethoxyacrylate (8.27 g, 48.9 mmol) was added to the filtrate at 0 ° C., and the mixture was stirred at the same temperature for 1 hour. The precipitated solid was collected by filtration and washed with methanol and ether cooled at 0 ° C. To the obtained solid was added 0.5 mol / L aqueous sodium hydroxide solution (48.9 mL, 24.3 mmol), and the mixture was stirred at 50 ° C. for 30 min. The reaction solution was filtered to remove insolubles, and then a 2N aqueous hydrochloric acid solution was added to the filtrate cooled to 0 ° C. to adjust the pH to about 1. The precipitated solid was collected by filtration to give the title compound (935 mg, 5.59 mmol, 23%) as a white solid.
1H-NMR (400 MHz, CD3OD) δ 2.62 (s, 3H), 8.37 (s, 1H).

Step 2: 4-hydroxy-2- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) pyrimidine-5-carbonitrile
4-Methoxy-4- (1) was added to a solution of 4-hydroxy-2- (methylthio) pyrimidine-5-carbonitrile (56.2 mg, 0.336 mmol) and acetic acid (385 μL, 6.72 mmol) in t-butanol (1.7 mL). After adding -methyl-1H-pyrazol-4-yl) aniline (89.0 mg, 0.437 mmol), the mixture was stirred for 3 hours under microwave irradiation. The reaction solution was poured into water and the precipitated solid was collected by filtration to give the title compound (69.1 mg, 0.214 mmol, 64%) as a yellow solid.
1H-NMR (300 MHz, DMSO-d6) δ 3.86 (s, 6H), 7.20 (dd, J = 8.3, 1.2 Hz, 1H), 7.38 (d, J = 1.2 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.84 (s, 1H), 8.05 (s, 1H), 8.35 (s, 1H), 10.11 (s, 1H).

Step 3: 4-Chloro-2- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) pyrimidine-5-carbonitrile
4-hydroxy-2- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) pyrimidine-5-carbonitrile (54.3 mg, 0.168 mmol) phosphorus oxychloride (1.0 mL) The solution was stirred at 80 ° C. for 2 hours. The solvent was concentrated under reduced pressure, and the obtained residue was solidified with hexane / ethyl acetate to give the title compound (77.6 mg) as a yellow solid.
1H-NMR (300 MHz, DMSO-d6) δ 3.86 (s, 3H), 3.87 (s, 3H), 7.30 (br s, 1H), 7.48 (s, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.90 (s, 1H), 8.09 (s, 1H), 8.91 (s, 1H), 10.86 (s, 1H).

Step 4: 4- (Cyclohexylamino) -2- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) pyrimidine-5-carbonitrile
4-Chloro-2- (3-methoxy-4- (1-methyl-1H-pyrazol-4-yl) phenylamino) pyrimidine-5-carbonitrile (63.6 mg, 0.187 mmol), and DIEA (130 μL, 0.747 mmol) in dioxane (2.0 mL) was added cyclohexylamine (64 μL, 0.560 mmol), and the mixture was stirred at 80 ° C. for 4 hours. Water and ethyl acetate were added to the reaction solution and separated. The aqueous phase was extracted with ethyl acetate, and the combined organic phases were washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and then concentrated under reduced pressure. Ethyl acetate / hexane was added to the obtained residue to solidify it, and the title compound (50.8 mg, 0.126 mmol, 68%) was obtained as a yellow solid by filtration.
1H-NMR (300MHz, DMSO-d6) δ: 1.10-1.49 (5H, m), 1.62-1.67 (5H, m), 3.86 (6H, s), 3.98-4.09 (1H, m), 7.42-7.45 ( 4H, m), 7.83 (1H, s), 8.03 (1H, s), 8.33 (1H, s), 9.74 (1H, br s).
MS (ESI) m / z = 404 (M + H) + .
LC / MS t R = 1.90 min.

Example 1-83
2- (5- (3-Cyclopentyl-1-methyl-2-oxo-2,3-dihydro-1H-imidazo [4,5-b] pyridin-5-ylamino) -2- (1-methyl-1H- Pyrazol-4-yl) phenoxy) acetonitrile

Step 1: 6-chloro-N 2 -cyclopentylpyridine-2,3-diamine
To a solution of 2,6-dichloropyridin-3-amine (1.63 g, 10 mmol) in NMP (10 mL) was added cyclopentylamine (4.93 mL, 50 mmol) and then at 200 ° C. for 10 hours under microwave irradiation. Stir. After water and ethyl acetate were added to the reaction solution and separated, the aqueous phase was extracted with ethyl acetate, and the combined organic phase was washed with water and saturated brine, and dried over magnesium sulfate. The organic phase was filtered and concentrated under reduced pressure. The resulting residue was purified by medium pressure silica gel chromatography (hexane / ethyl acetate: 10-30% ethyl acetate gradient) to give the title compound (2.33 g, 11.0 mmol, 100 %).
1H-NMR (300 MHz, DMSO-d6) δ 1.36-1.73 (m, 6H), 1.95-1.99 (m, 3H), 4.12-4.17 (m, 1H), 4.84 (s, 2H), 5.69 (d, J = 6.5 Hz, 1H), 6.30 (d, J = 7.7 Hz, 1H), 6.64 (d, J = 7.7 Hz, 1H).

Step 2: 5-chloro-3-cyclopentyl-1H-imidazo [4,5-b] pyridin-2 (3H) -one
6-Chloro-N 2 -cyclopentylpyridine-2,3-diamine (2.33 g, 11.0 mmol) and sodium bicarbonate (2.77 g, 33.0 mmol) in water / ethyl acetate (10 mL / 25 mL) solution in phenylchloro Formate (2.07 mL, 16.5 mmol) was added dropwise at 0 ° C., and the mixture was stirred at 70 ° C. for 2 hours. The reaction solution was returned to room temperature, the organic phase was separated and extracted, and then the solvent was concentrated under reduced pressure. The obtained residue was solidified with isopropyl ether to give the title compound (1.54 g, 6.48 mmol, 59%).
1H-NMR (300 MHz, DMSO-d6) δ 1.61-1.63 (m, 2H), 1.90-1.92 (m, 5H), 2.08-2.17 (m, 2H), 4.66-4.77 (m, 1H), 7.04 ( d, J = 8.1 Hz, 1H), 7.31 (d, J = 8.1 Hz, 1H), 11.27 (s, 1H).

Step 3: 5-chloro-3-cyclopentyl-1-methyl-1H-imidazo [4,5-b] pyridin-2 (3H) -one
5-chloro-3-cyclopentyl-1H-imidazo [4,5-b] pyridin-2 (3H) -one (770 mg, 3.24 mmol) and 60% sodium hydride (194 mg, 4.86 mmol) in DMF ( To the 5.0 mL) solution, methyl iodide (0.304 mL, 4.86 mmol) was added dropwise at 0 ° C., and the mixture was stirred at room temperature for 1 hour. The reaction solution was returned to room temperature, poured into ice water, and the resulting solid was collected by filtration to give the title compound (602 mg, 2.39 mmol, 74%).
1H-NMR (300 MHz, DMSO-d6) δ 1.60-1.67 (m, 2H), 1.84-1.94 (m, 5H), 2.09-2.14 (m, 2H), 3.33 (s, 3H), 4.70-4.81 ( m, 1H), 7.14 (d, J = 8.1 Hz, 1H), 7.54 (d, J = 8.1 Hz, 1H).

Step 4: 2- (5- (3-Cyclopentyl-1-methyl-2-oxo-2,3-dihydro-1H-imidazo [4,5-b] pyridin-5-ylamino) -2- (1-methyl -1H-pyrazol-4-yl) phenoxy) acetonitrile The title compound (85.9 mg, 0.194 mmol, 49%) was obtained in the same manner as in Example 1-1 / Step 2.
1H-NMR (300 MHz, DMSO-d6) δ 1.64-1.66 (m, 2H), 1.94-1.97 (m, 4H), 2.21-2.28 (m, 2H), 3.29 (s, 3H), 3.86 (s, 3H), 4.83-4.86 (m, 1H), 5.18 (s, 2H), 6.58 (d, J = 8.4 Hz, 1H), 7.32 (dd, J = 8.4, 2.0 Hz, 1H), 7.41 (d, J = 8.4 Hz, 1H), 7.46-7.48 (m, 2H), 7.80 (s, 1H), 8.00 (s, 1H), 9.04 (s, 1H).
MS (ESI) m / z = 444 (M + H) + .
LC / MS t R = 1.70 min.

Example 1-84
2- (5- (3- (cyanomethoxy) -4- (1-methyl-1H-pyrazol-4-yl) phenylamino) -3-cyclopentyl-2-oxo-2,3-dihydro-1H-imidazo [ 4,5-b] pyridin-1-yl) acetonitrile

The title compound was synthesized according to the method of Example 1-83.
1H-NMR (300 MHz, DMSO-d6) δ 1.64-1.66 (m, 2H), 1.94-1.99 (m, 4H), 2.20-2.23 (m, 2H), 3.86 (s, 3H), 4.84-4.86 ( m, 1H), 5.08 (s, 2H), 5.19 (s, 2H), 6.63 (d, J = 8.4 Hz, 1H), 7.31 (dd, J = 8.5, 1.9 Hz, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.49 (d, J = 8.5 Hz, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.80 (s, 1H), 8.00 (s, 1H), 9.16 (s, 1H ).
MS (ESI) m / z = 469 (M + H) + .
LC / MS t R = 1.71 min.

Example 1-85
2- (5- (3- (cyanomethoxy) -4- (1-methyl-1H-pyrazol-4-yl) phenylamino) -2-oxo-3- (tetrahydro-2H-pyran-4-yl)- 2,3-Dihydro-1H-imidazo [4,5-b] pyridin-1-yl) acetonitrile

The title compound was synthesized according to the method of Example 1-83.
1H-NMR (DMSO-d6) δ 1.67-1.69 (m, 2H), 2.61-2.73 (m, 2H), 3.47 (t, J = 11.5 Hz, 2H), 3.86 (s, 3H), 4.02 (dd, J = 11.6, 3.9 Hz, 2H), 4.45-4.49 (m, 1H), 5.23 (s, 2H), 6.55 (d, J = 8.4 Hz, 1H), 7.11 (dd, J = 8.5, 1.9 Hz, 1H ), 7.24 (d, J = 8.4 Hz, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.79 (d, J = 0.5 Hz, 1H), 7.98 (s, 1H), 9.02 (s, 1H), 10.76 (s, 1H).
MS (ESI) m / z = 446 (M + H) + .
LC / MS t R = 1.28 min.

Example 1-86
4- (6- (3- (cyanomethoxy) -4- (1-methyl-1H-pyrazol-4-yl) phenylamino) -2- (cyclohexylamino) pyridin-3-yl) -N-cyclopropylbenzamide

The title compound was synthesized according to the method of Example 1-15.
1H-NMR (DMSO-d6) δ 0.58-0.59 (m, 2H), 0.68-0.71 (m, 2H), 1.22-1.36 (m, 5H), 1.67-1.69 (m, 3H), 1.95-1.99 (m , 2H), 2.86-2.87 (m, 1H), 3.84-3.88 (m, 4H), 5.13 (s, 3H), 6.16 (d, J = 8.1 Hz, 1H), 7.21-7.24 (m, 2H), 7.46 (dd, J = 8.4, 3.1 Hz, 3H), 7.75 (dd, J = 8.5, 1.8 Hz, 1H), 7.80 (s, 1H), 7.87 (d, J = 8.2 Hz, 2H), 8.01 (s , 1H), 8.43 (d, J = 4.3 Hz, 1H), 9.03 (s, 1H).
MS (ESI) m / z = 562 (M + H) + .
LC / MS t R = 1.95 min.





















(Example 2) Results of TTK assay and A549 assay Typical results of the TTK assay and A549 assay are shown below.
Table 7


(Example 3) CYP3A4 fluorescence MBI test
The CYP3A4 fluorescence MBI test is a test to examine the enhancement of CYP3A4 inhibition of compounds by metabolic reaction. 7-Benzyloxytrifluoromethylcoumarin (BFC) is debenzylated by CYP3A4 enzyme using E. coli-expressed CYP3A4 as the enzyme, and fluorescence The reaction that produces the metabolite 7-Hydroxytrifluoromethylcoumarin (HFC), which emits, was performed as an index.

The reaction conditions are as follows: substrate, 5.6 μmol / L 7-BFC; pre-reaction time, 0 or 30 minutes;
Reaction time, 15 minutes; Reaction temperature, 25 ° C. (room temperature); CYP3A4 content (E. coli expression enzyme), pre-reaction 62.5 pmol / mL, reaction 6.25 pmol / mL (10-fold dilution); test drug concentration, 0.625 1.25
2.50, 5.00, 10.0, 20.0 μmol / L (6 points).

  Add the enzyme and test drug solution to the 96-well plate as a pre-reaction solution in K-Pi buffer (pH 7.4) with the above pre-reaction composition, and add the substrate and K-Pi buffer to the other 96-well plate. A portion of the solution was transferred so that it was diluted by 10/10, and the reaction using NADPH, a coenzyme, was started as an indicator (no pre-reaction). After a predetermined time of reaction, acetonitrile: 0.5 mol / L Tris ( The reaction was stopped by adding (trishydroxyaminomethane) = 4: 1. Also, add NADPH to the remaining pre-reaction solution to start the pre-reaction (with pre-reaction). After the pre-reaction for a predetermined time, add another plate and dilute 1/10 with the substrate and K-Pi buffer. The reaction was started by shifting the part. After the reaction for a predetermined time, the reaction was stopped by adding acetonitrile: 0.5 mol / L Tris (trishydroxyaminomethane)-= 4: 1. The fluorescence value of 7-HFC, which is a metabolite, was measured using a fluorescent plate reader on the plate on which each index reaction was performed (Ex = 420 nm, Em = 535 nm).

The control (100%) was obtained by adding DMSO, which is a solvent in which the drug was dissolved, to the reaction system, and the residual activity (%) at each concentration of the test drug solution was calculated. The IC 50 was calculated by inverse estimation using a logistic model. The case where the difference in IC 50 value was 5 μM or more was designated as (+), and the case where it was 3 μM or less was designated as (−).

Example 4 CYP Inhibition Test 7-ethoxyresorufin O-deethylation as a typical substrate metabolic reaction of human tumor CYP5 molecular species (CYP1A2, 2C9, 2C19, 2D6, 3A4) using commercially available pooled human liver microsomes (CYP1A2), methyl-hydroxylation of tolbutamide (CYP2C9), mephenytoin 4'-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), terfenadine hydroxylation (CYP3A4) The degree to which the amount of each metabolite produced was inhibited by the test compound was evaluated.

  The reaction conditions are as follows: substrate, 0.5 μmol / L ethoxyresorufin (CYP1A2), 100 μmol / L tolbutamide (CYP2C9), 50 μmol / L S-mephenytoin (CYP2C19), 5 μmol / L dextromethorphan (CYP2D6) ), 1 μmol / L terfenadine (CYP3A4); reaction time, 15 minutes; reaction temperature, 37 ° C; enzyme, pooled human liver microsome 0.2 mg protein / mL; test drug concentration, 1.0, 5.0, 10, 20 μmol / L ( 4 points).

  As a reaction solution in a 96-well plate, add 5 types of each substrate, human liver microsome and test drug in 50 mM Hepes buffer with the above composition, add coenzyme NADPH, and perform metabolic reaction as an index. After starting and reacting at 37 ° C. for 15 minutes, the reaction was stopped by adding a methanol / acetonitrile = 1/1 (v / v) solution. After centrifuging at 3000 rpm for 15 minutes, resorufin (CYP1A2 metabolite) in the supernatant of the supernatant was collected using a fluorescent multi-label counter with tolbutamide hydroxide (CYP2C9 metabolite) and mephenytoin 4 'hydroxide (CYP2C19 metabolite). Then, dextrorphan (CYP2D6 metabolite) and terfenadine alcohol (CYP3A4 metabolite) were quantified by LC / MS / MS.

The control (100%) was obtained by adding only DMSO, which is a solvent in which the drug was dissolved, to the reaction system, and the residual activity (%) at each concentration of the test drug solution was calculated. The IC 50 was calculated by inverse estimation using a logistic model.

(Example 5) FAT test Inoculate 20 μL of Salmonella typhimurium TA98 strain, TA100 strain frozen into 10 mL liquid nutrient medium (2.5% Oxoid nutrient broth No. 2) for 10 hours at 37 ° C. Incubated before shaking. For TA98 strain, 9 mL of the bacterial solution was centrifuged (2000 × g, 10 minutes) to remove the culture solution, and 9 mL of Micro F buffer solution (K 2 HPO 4 : 3.5 g / L, KH2PO4: 1 g / L, ( NH 4 ) 2 SO 4 : 1 g / L, trisodium citrate dihydrate: 0.25 g / L, MgSO 4 · 7H 2 0: 0.1 g / L), and 110 mL of exposure medium (biotin) : Micro F buffer solution containing 8 μg / mL, histidine: 0.2 μg / mL, glucose: 8 mg / mL), and TA100 strain was added to 120 mL of Exposure medium to 3.16 mL bacterial solution to prepare a test bacterial solution . Test substance DMSO solution (maximum dose 50 mg / mL to 8-fold dilution at 2-fold common ratio), DMSO as negative control, 50 μg / mL 4-nitroquinoline for TA98 strain under non-metabolic activation conditions as positive control -1-oxide DMSO solution, TA100 strain, 0.25 μg / mL 2- (2-furyl) -3- (5-nitro-2-furyl) acrylamide DMSO solution, metabolic activation conditions against TA98 strain 40 μg / mL 2-aminoanthracene DMSO solution and 20 μg / mL 2-aminoanthracene DMSO solution for TA100 strain, respectively, and 588 μL of the test bacterial solution (498 μL of the test bacterial solution under metabolic activation conditions) And S9 mix 90 μL) were mixed, and cultured at 37 ° C. for 90 minutes with shaking. 460 μL of bacterial solution exposed to the test substance is added to Indicator Medium (MicroF buffer solution containing biotin: 8 μg / mL, histidine: 0.2 μg / mL, glucose: 8 mg / mL, bromocresol purple: 37.5 μg / mL) 2300 50 μL each was mixed in μL, dispensed into 48 microwells / dose of the microplate, and statically cultured at 37 ° C. for 3 days. Since wells containing bacteria that have acquired growth ability due to mutations in the amino acid (histidine) synthase gene turn from purple to yellow due to pH change, count the number of bacterial growth wells that turn yellow in 48 wells per dose. Evaluation was made in comparison with the negative control group.

(Example 6) Solubility test The solubility of the compound was determined under the condition of addition of 1% DMSO. Prepare 10 mM compound solution in DMSO, add 6 μL of the compound solution to pH 6.8 artificial intestinal fluid (0.2 mol / L potassium dihydrogen phosphate reagent 250 mL, 0.2 mL / L NaOH reagent 118 mL, and water to 1000 mL. Added to 594 μL. After allowing to stand at 25 ° C. for 16 hours, the mixed solution was subjected to suction filtration. The filtrate was diluted 2-fold with methanol / water = 1/1, and the concentration in the filtrate was measured by HPLC or LC / MS / MS by the absolute calibration curve method.

(Example 7) Metabolic stability test Using commercially available pooled human liver microsomes, the target compound was reacted for a certain period of time, and the residual rate was calculated by comparing the reaction sample with the unreacted sample to evaluate the degree of metabolism in the liver. .

  Presence of 1 mmol / L NADPH in 0.2 mL buffer (50 mmol / L tris-HCl pH7.4, 150 mmol / L potassium chloride, 10 mmol / L magnesium chloride) containing 0.5 mg protein / mL human liver microsomes The reaction was allowed to proceed at 37 ° C. for 0 or 30 minutes (oxidative reaction). After the reaction, 50 μL of the reaction solution was added to 100 μL of a methanol / acetonitrile = 1/1 (v / v) solution, mixed, and centrifuged at 3000 rpm for 15 minutes. The test compound in the centrifugal supernatant was quantified by LC / MS / MS, and the remaining amount of the test compound after the reaction was calculated with the amount of the compound at 0 minute reaction as 100%.

(Example 8) hERG test For the purpose of risk assessment of ECG QT interval prolongation, using HEK293 cells expressing human ether-a-go-go related gene (hERG) channel, an important role in ventricular repolarization process We investigated the effect on delayed rectifier K + current (IKr).

Using a fully automatic patch clamp system (PatchXpress 7000A, Axon Instruments Inc.) and holding the cells at a membrane potential of -80 mV by whole cell patch clamp method, +50 mV depolarization stimulation was further applied for 2 seconds. IKr induced when 50 mV of repolarization stimulus was applied for 2 seconds was recorded. After the generated current has stabilized, the extracellular fluid (NaCl: 137 mmol / L, KCl: 4 mmol / L, CaCl 2・ 2H 2 O: 1.8 mmol) in which the test substance is dissolved at the target concentration (1.0 μM) / L, MgCl 2 · 6H 2 O: 1 mmol / L, glucose: 10 mmol / L, HEPES (4- (2-hydroxyethyl) -1-piperazineethane-sulfonic acid, 4- (2-hydroxyethyl) -1- Piperazine ethanesulfonic acid): 10 mmol / L, pH- = 7.4) was applied to the cells for 10 minutes at room temperature. The absolute value of the maximum tail current was measured from the obtained IKr using analysis software (DataXpress ver. 1, Molecular Devices Corporation) based on the current value at the holding membrane potential. Furthermore, the inhibition rate with respect to the maximum tail current before application of the test substance was calculated, and compared with the medium application group (0.1% dimethyl sulfoxide solution), the influence of the test substance on IKr was evaluated.

(Example 9: Formulation example 1 tablet)
A tablet having the following composition is produced by a conventional method.
100 mg of the compound of the present invention
Lactose 60mg
Potato starch 30mg
Polyvinyl alcohol 2mg
Magnesium stearate 1mg
Tar pigment Trace amount.

(Example 10: Formulation example 2 powder)
A powder having the following composition is produced by a conventional method.
150 mg of the compound of the present invention
Lactose 280 mg.

(Example 11: Formulation example 3 syrup)
A syrup having the following composition is produced by a conventional method.
100 mg of the compound of the present invention
Purified white sugar 40 g
40 mg ethyl p-hydroxybenzoate
Propyl p-hydroxybenzoate 10mg
Chocolate flavor 0.1cc
Water is added to make a total amount of 100 cc.

  As mentioned above, although this invention has been illustrated using preferable embodiment of this invention, this invention should not be limited and limited to this embodiment. It is understood that the scope of the present invention should be construed only by the claims. It is understood that those skilled in the art can implement an equivalent range based on the description of the present invention and the common general technical knowledge from the description of specific preferred embodiments of the present invention. Patents, patent applications, and documents cited herein should be incorporated by reference in their entirety, as if the contents themselves were specifically described herein. Understood.

  This application is based on patent application No. 2009-183833 filed in Japan, the contents of which are incorporated in full herein.

  The present invention provides a medicament for treating a TTK kinase-dependent disease, a compound used therefor, a pharmaceutically acceptable salt thereof, or a solvate thereof. The compound of the present invention exhibits an excellent TTK kinase inhibitory action as described in the above Examples.

Claims (19)

  1. Formula (I):

    (Where
    X is = C (R 4 )-or = N-
    A represents a substituted or unsubstituted aromatic hydrocarbon ring, a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyrazole or fused pyrazole), a substituted or unsubstituted non-aromatic hydrocarbon ring. Or a substituted or unsubstituted non-aromatic heterocycle,
    R 1 is hydrogen, substituted or unsubstituted alkyl, a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B ;
    R 1A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl or substituted or Unsubstituted saturated heterocyclyl,
    R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Substituted saturated heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl,
    R 1B is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Saturated heterocyclyl, substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl,
    R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl , Substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino, halogen, carboxy or hydrogen, or
    R 1 and R 2 together with the adjacent carbon atom
    Formula (II):

    (Where
    R 1A ″ and R 2A ″ each independently represent hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl Substituted or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl,
    R a and R b are each independently hydrogen or substituted or unsubstituted alkyl;
    n is an integer of 0-3. ) May be formed,
    R 3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or halogen;
    R 4 is hydrogen or halogen;
    R 5A and R 5B are each independently hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted Cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, substituted or unsubstituted acyl, substituted or unsubstituted alkoxy, substituted or An unsubstituted carbamoyl, a group represented by the formula: —SO 2 —R ′, a group represented by the formula: —SO—R ′, or a group represented by the formula: —SR ′;
    R ′ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl It is.
    However,
    (I) X is ═C (R 4 ) —, and A is substituted or unsubstituted piperidine, substituted or unsubstituted thiophene, substituted or unsubstituted tetrahydropyran, substituted or unsubstituted fused pyrimidine, substituted or non-substituted When substituted condensed pyridine or substituted or unsubstituted tetrahydrofuran, R 2 is cyano;
    (Ii) when X is ═C (R 4 ) —, A is a substituted or unsubstituted aromatic hydrocarbon ring, and R 2 is nitro, R 1 is of the formula: —NR 1A R 1A ′ In which R 1A ′ is phenylethyl and the group represented by the formula: —OR 1B (where R 1B is methyl)
    (Iii) When X is ═C (R 4 ) — and A is a substituted or unsubstituted non-aromatic hydrocarbon ring, R 1 is a group represented by the formula: —NR 1A R 1A ′ (here R 1A ′ is substituted or unsubstituted alkyl) and a group represented by the formula: —OR 1B (where R 1B is substituted or unsubstituted alkyl),
    (Iv) X is ═C (R 4 ) —, A is a substituted or unsubstituted aromatic hydrocarbon ring, R 2 is cyano, and R 1 is represented by the formula: —NR 1A R 1A ′ Wherein R 1A ′ is a substituted or unsubstituted alkyl or a group of the formula: —OR 1B (where R 1B is methyl or ethyl), R 3 is hydrogen,
    (V) When X is ═C (R 4 ) — and A is a non-aromatic heterocyclic ring, R 1 is a group represented by the formula: —NR 1A R 1A ′ (where R 1A ′ is Instead of substituted or unsubstituted alkyl)
    (Vi) when X is ═C (R 4 ) —, the number of hydrogens in R 1 , R 3 and R 4 is 2 or less;
    (Vii) When X is = N-, A is a substituted or unsubstituted aromatic hydrocarbon ring or a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyridine). , R 2 is cyano, R 3 is hydrogen, R 1 is a group represented by the formula: —NR 1A R 1A ′ (where R 1A ′ is a substituted or unsubstituted alkyl, substituted or unsubstituted Piperidinyl and substituted or unsubstituted cyclopropyl) and a group represented by the formula: —OR 1B (where R 1B is substituted or unsubstituted alkyl),
    (Viii) When X is = N-, A is a substituted or unsubstituted aromatic hydrocarbon ring or a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyridine). , R 2 is cyano, R 3 is hydrogen and R 5A is not substituted sulfinyl, substituted or unsubstituted carbamoyl, carboxy, substituted or unsubstituted morpholinyl and substituted sulfonyl.
    ) A compound represented by the following formula (however, the compound shown below:

    except for. ), Pharmaceutically acceptable salts or solvates thereof.
  2. R 1 is a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B (wherein R 1A , R 1A ′ and R 1B are as defined in claim 1),
    R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl The compound according to claim 1, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R is a substituted, unsubstituted or carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino or carboxy object.
  3. The compound according to claim 1 or 2, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein A is a substituted or unsubstituted aromatic hydrocarbon ring.
  4. X is = C (R 4) - (wherein, R 4 is claim 1 as defined) is, according to claim 1 or 2 A compound according, or a pharmaceutically acceptable salt or solvate thereof.
  5. The compound according to claim 1 or 2, wherein X is = CH-, a pharmaceutically acceptable salt thereof, or a solvate thereof.
  6. R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, The compound, its pharmaceutically acceptable salt or solvate thereof according to claim 1 or 2, which is substituted or unsubstituted alkoxycarbonyl, substituted amino or carboxy.
  7. The compound according to claim 1, wherein R 2 is cyano, a pharmaceutically acceptable salt thereof, or a solvate thereof.
  8. The compound according to claim 1, wherein R 3 is hydrogen, a pharmaceutically acceptable salt thereof, or a solvate thereof.
  9. 3. R 1 is a group represented by the formula: —NHR 1A ′ or a group represented by the formula: —OR 1B (wherein R 1A ′ and R 1B are as defined in claim 1), Compound, its pharmaceutically acceptable salt or solvate thereof.
  10. 2. R 1 is a group represented by the formula: —NHR 1A ′ , and R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted saturated heterocyclyl. Or the compound according to 2, a pharmaceutically acceptable salt thereof, or a solvate thereof.
  11. R 1 has the formula: a group represented by -OR 1B, R 1B is a substituted or unsubstituted cycloalkyl, claim 1 or 2 A compound according, salts or solvates are pharmaceutically acceptable .
  12. Formula (III):

    A group represented by
    Formula (IV):

    Or a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 1, wherein R 5A and R 5B are as defined in claim 1.
  13. The compound according to claim 1 or 2, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R 5A is substituted or unsubstituted heteroaryl or substituted or unsubstituted alkenyl.
  14. The compound according to claim 1 or 2, wherein R 5A is substituted or unsubstituted pyrazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted oxazolyl, substituted or unsubstituted oxadiazolyl, or substituted or unsubstituted alkenyl, A pharmaceutically acceptable salt or a solvate thereof.
  15. The compound according to claim 1 or 2, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R 5B is hydrogen, substituted or unsubstituted alkoxy, substituted or unsubstituted amino, or substituted or unsubstituted alkyl. .
  16. X is = C (R 4 )-(where R 4 is as defined in claim 1);
    R 1 and R 2 together with adjacent carbon atoms
    Formula (II):

    Wherein R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl or substituted or unsubstituted cycloalkyl,
    n is an integer of 0 to 2, and R a and R b are the same as defined in claim 1),
    A is a substituted or unsubstituted aromatic hydrocarbon ring,
    The compound according to claim 1, wherein R 3 is hydrogen, a pharmaceutically acceptable salt thereof, or a solvate thereof.
  17. The pharmaceutical composition containing the compound in any one of Claims 1-16, its pharmaceutically acceptable salt, or those solvates.
  18. The pharmaceutical composition according to claim 17, which is a TTK inhibitor.
  19. Formula (I):

    (Where
    X is = C (R 4 )-
    A represents a substituted or unsubstituted aromatic hydrocarbon ring, a substituted or unsubstituted aromatic heterocyclic ring (excluding substituted or unsubstituted pyrazole or fused pyrazole and substituted or unsubstituted thiophene), substituted or unsubstituted A non-aromatic hydrocarbon ring or a substituted or unsubstituted non-aromatic heterocyclic ring,
    R 1 is hydrogen, substituted or unsubstituted alkyl, a group represented by the formula: —NR 1A R 1A ′ or a group represented by the formula: —OR 1B ;
    R 1A is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl or substituted or Unsubstituted saturated heterocyclyl,
    R 1A ′ is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted A substituted saturated heterocyclyl;
    R 1B is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted Of saturated heterocyclyl
    R 2 is cyano, nitro, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl , Substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted or unsubstituted alkoxycarbonyl, substituted amino, halogen, carboxy or hydrogen, or
    R 1 and R 2 together with the adjacent carbon atom
    Formula (II):

    (Where
    R 1A ″ and R 2A ″ are each independently substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted carbamoyl, substituted or unsubstituted acyl, substituted Or unsubstituted cycloalkyl or substituted or unsubstituted saturated heterocyclyl,
    R a and R b are each independently hydrogen or substituted or unsubstituted alkyl;
    n is an integer of 0-3. )
    R 3 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl or halogen;
    R 4 is hydrogen or halogen;
    R 5A and R 5B are each independently hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl Substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted amino, substituted or unsubstituted acyl, substituted or unsubstituted alkoxy, substituted or unsubstituted Carbamoyl, a group represented by the formula: —SO 2 —R ′, a group represented by the formula: —SO—R ′, or a group represented by the formula: —SR ′;
    R ′ is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl The pharmaceutical composition which has TTK inhibitory activity containing the compound which is these, its pharmaceutically acceptable salt, or those solvates.
JP2010121046A 2009-08-06 2010-05-26 Pyridine and pyrimidine derivative having ttk-inhibiting action Pending JP2012197231A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2009183833 2009-08-06
JP2009183833 2009-08-06
JP2010121046A JP2012197231A (en) 2009-08-06 2010-05-26 Pyridine and pyrimidine derivative having ttk-inhibiting action

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010121046A JP2012197231A (en) 2009-08-06 2010-05-26 Pyridine and pyrimidine derivative having ttk-inhibiting action
TW99125727A TW201109331A (en) 2009-08-06 2010-08-03 Pyridine and pyrimidine derivatives having ttk-inhibiting activity
PCT/JP2010/063153 WO2011016472A1 (en) 2009-08-06 2010-08-04 Pyridine and pyrimidine derivatives having ttk-inhibiting activity

Publications (1)

Publication Number Publication Date
JP2012197231A true JP2012197231A (en) 2012-10-18

Family

ID=43544367

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010121046A Pending JP2012197231A (en) 2009-08-06 2010-05-26 Pyridine and pyrimidine derivative having ttk-inhibiting action

Country Status (3)

Country Link
JP (1) JP2012197231A (en)
TW (1) TW201109331A (en)
WO (1) WO2011016472A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523941A (en) * 2013-07-09 2016-08-12 バイエル ファーマ アクチエンゲゼルシャフト Modified BET protein inhibitory dihydroquinoxalinones and dihydropyridopyrazinones

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
NZ614776A (en) 2011-04-22 2015-06-26 Signal Pharm Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
US9351974B2 (en) 2011-11-10 2016-05-31 OSI Pharmaceuticals, LLC Substituted pteridinones for the treatment of cancer
RU2647849C2 (en) * 2011-11-29 2018-03-21 Дженентек, Инк. 2-(phenyl or pyrid-3-yl)aminopyrimidine derivatives as modulators of leucine-rich repeating kinase 2 (lrrk2) for treatment of parkinson's disease
EP2861595B9 (en) 2012-06-13 2017-06-21 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
CA2895404A1 (en) * 2012-12-20 2014-06-26 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydropyridopyrazinones
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
SG11201704827UA (en) 2014-12-16 2017-07-28 Signal Pharm Llc Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX2017010673A (en) 2015-02-20 2018-03-21 Incyte Corp Bicyclic heterocycles as fgfr inhibitors.
EA201791867A1 (en) 2015-02-20 2017-12-29 Инсайт Корпорейшн Bicyclic heterocycles as fgfr4 inhibitors
CN107567503A (en) * 2015-04-17 2018-01-09 荷兰转化研究中心有限责任公司 Prognosis biomarker for TTK inhibitor chemotherapy
CN106279150B (en) * 2015-06-10 2018-02-09 中国人民解放军军事医学科学院毒物药物研究所 Thick cyclics of pyridine and its production and use
MX2018001004A (en) 2015-07-24 2018-06-07 Celgene Corp Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein.
CA3046339A1 (en) 2016-12-20 2018-06-28 Astrazeneca Ab Amino-triazolopyridine compounds and their use in treating cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2187492A (en) * 1991-06-12 1993-01-12 E.I. Du Pont De Nemours And Company Substituted pyridine herbicides
HU0004024A3 (en) * 1997-09-26 2001-10-29 Zentaris Gmbh Azabenzimidazole-based compounds, process for their preparation and pharmaceutical composition thereof
JP4406515B2 (en) * 2001-04-09 2010-01-27 富士フイルム株式会社 Azo compound, coloring composition, ink composition, and ink jet recording method
GB0113041D0 (en) * 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
WO2005023761A2 (en) * 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
AR051788A1 (en) * 2004-12-08 2007-02-07 Janssen Pharmaceutica Nv Derivatives 2,4 (4,6) pyrimidine as kinase inhibitors
MX2007012393A (en) * 2005-04-05 2008-02-22 Pharmacopeia Inc Purine and imidazopyridine derivatives for immunosuppression.
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EP1951684B1 (en) * 2005-11-01 2016-07-13 TargeGen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
NZ580671A (en) * 2007-04-16 2012-03-30 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
TW201028381A (en) * 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523941A (en) * 2013-07-09 2016-08-12 バイエル ファーマ アクチエンゲゼルシャフト Modified BET protein inhibitory dihydroquinoxalinones and dihydropyridopyrazinones

Also Published As

Publication number Publication date
TW201109331A (en) 2011-03-16
WO2011016472A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
RU2394825C2 (en) Pyrrolopyrazines suitable as aurora a kinase inhibitors
JP5642963B2 (en) Pyridinonyl PDK1 inhibitor
KR101955871B1 (en) Aryl- or heteroaryl-substituted benzene compounds
KR101975613B1 (en) Substituted benzene compounds
CN1308327C (en) Imidazopyridine derivatives
US8063055B2 (en) Substituted pyridone compounds and methods of use
KR101764076B1 (en) Pyrimidine derivatives useful as raf kinase inhibitors
KR101466412B1 (en) Pyrrolopyrimidine compounds and their uses
CN101175753B (en) Compounds and compositions as protein kinase inhibitors
CN1186324C (en) Condensed heteroaryl derivatives
ES2345629T3 (en) Pirrolopiridine derivatives as protein kinase inhibitors.
DK2857404T3 (en) IMIDAZO [1,2-b] PYRIDAZINE DERIVATIVES AS KINase INHIBITORS
JP5699149B2 (en) Bruton type tyrosine kinase inhibitor
US8106068B2 (en) Compositions and methods for modulating c-kit and PDGFR receptors
RU2615130C2 (en) Heterocyclic compounds useful as pdk1 inhibitors
CA2718528C (en) Substituted 4-hydroxypyrimidine-5-carboxamides
US9371331B2 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
JP2010514693A (en) Quinazoline for PDK1 inhibition
CA2681015C (en) Inhibitors of focal adhesion kinase
US10131664B2 (en) Inhibitors of lysine specific demethylase-1
AU2008273017C1 (en) Heterocyclic compounds useful as Raf kinase inhibitors
CN101511798B (en) [4,5']bipyrimidinyl-6,4'-diamine derivatives as protein kinase inhbitors
KR20140075693A (en) Heterocyclic compounds and uses thereof
WO2011119518A1 (en) Soluble guanylate cyclase activators
AU2007263017A1 (en) Pyridine and pyrazine derivatives as MNK kinase inhibitors